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This thesis describes our efforts toward the development of a dynamic 
combinatorial library using pyrrolo[1,3]-diazepines. During our work, I have demonstrated the 
ability to hydrolyze and recyclize the diazepine core via the condensation of several different 
aldehydes to afford novel diazepine derivatives. Additionally, I have been able to modulate the 
electronic and steric properties of the diazepine scaffold through substitution on the pyrrole core. 
My work towards finding suitable conditions for a thermodynamically controlled dynamic 
exchange reaction have shown that while hydrolysis of the diazepine scaffold seems to be 
favored, recyclization of the resulting amine intermediate appears to be disfavored. As a second 
project I describe our efforts toward the development of a library of pyrimidinone-based 
potential poxvirus resolvase inhibitors. Utilizing the multi-component Biginelli reaction, I have 
synthesized a small library of pyrimidinones attached to potential chelating functionalities, 
including the di-keto acid moiety. Biological testing has resulted in the discovery of a carboxylic 
acid containing pyrimidinone (MAL1-265) that possesses moderate fowlpox resolvase inhibitory 
activity (IC50 16 µM). 
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PREFACE 
 I would like to thank all of my friends and family for their continued support. I would 
also like to dedicate this document to the memory of my grandfather Raymond Dietrich. 
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1.0  EFFORTS TOWARD THE DEVELOPMENT OF A DYNAMIC 
COMBINATORIAL LIBRARY USING PYRROLO[1,3]-DIAZEPINES 
1.1 INTRODUCTION 
Beginning in the mid 1990’s, dynamic combinatorial chemistry emerged as a powerful 
technique capable of creating large libraries where the composition is controlled by the relative 
thermodynamic stability of the components under a particular set of conditions.1-5 In simplistic 
terms, dynamic combinatorial chemistry may be considered “traditional combinatorial chemistry 
under thermodynamic control” as the two methods share several similarities.1 Dynamic 
combinatorial chemistry relies on the use of reversible reactions, be it noncovalent interactions 
(i.e. H-bonding or metal-ligand interactions)6-8 or covalent bonds, in order to generate complex 
libraries of compounds that are continuously interconverting until the minimum free energy of 
the system is achieved.1-2 One of the most useful aspects of dynamic combinatorial chemistry is 
that the library composition changes in response to environmental stimuli (i.e. pH or 
temperature), providing the opportunity to select molecules with a particular set of properties.2 
The library may also be manipulated via the addition of a template (i.e protein) in order to 
identify high-affinity binding molecules.9-10 Molecules with a high-affinity for the template bind 
and are removed from the library equilibrium. Following Le Chatelier’s principle, the library 
composition is redistributed to compensate for the substrate bound to the template; resulting in a 
net increase or amplification in the amount of the template-bound molecules (Scheme 1).  
2 
One of the drawbacks in employing dynamic combinatorial chemistry is that the method 
relies on the use of reversible reactions in order to achieve the desired thermodynamically 
controlled system. While the number of viable reversible reactions found in the literature has 
significantly increased during the last decade, there is a plethora of irreversible reactions that 
may be utilized in traditional combinatorial chemistry.1, 5 However, while dynamic combinatorial 
libraries require the use of reversible reactions synthesis, the identification of potential targets is 
extremely efficient in comparison to traditional combinatorial chemistry as targets may be 
identified in situ upon exposure to desired conditions or templates.5 Traditional combinatorial 
libraries on the other hand require that each member be individually synthesized and isolated 
prior to testing. Moreover, as each library member must be tested separately, there is an 
increased amount of time between library conception and isolation of a target compound. An 
additional concern when creating a dynamic combinatorial library is that in order to have the 
library under thermodynamic control every member of the library must be soluble; otherwise 
shifts in library composition may occur as a result of solubility instead of thermodynamic 
stability.5 Traditional combinatorial chemistry is able to avoid solubility issues as each target 
from a traditional library is isolated and tested separately, thus, insoluble library members have 
no effect on other members. Lastly, a noteworthy question is how large a dynamic combinatorial 
library should be in order to efficiently identify potential substrates. Generally, the larger a 
Scheme 1. Dynamic combinatorial chemistry. 
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traditional combinatorial library is the better the chances of finding potential targets is, however, 
larger dynamic combinatorial libraries are not necessarily always better.11 With an increased 
dynamic library size the probability of detecting every species present in the library is lowered, 
but the probability of detecting amplification is also increased due to the increased odds of the 
library containing a high-affinity binding molecule. While there are several disadvantages to 
using dynamic combinatorial chemistry in the investigation of potential drug targets or catalysts 
the concept remains a useful method for the rapid discovery of such molecules and has been 
applied in the investigation of several potential targets. 
 A dynamic combinatorial library was employed in the study of potential inhibitors of 
neuraminidase, a key enzyme in the propagation of the influenza virus.12 Utilizing an amine 
scaffold, a dynamic library was created via the condensation with a number of diversified 
aldehydes under imidazole/HCl buffered conditions (Scheme 2).  
Scheme 2. Dynamic combinatorial library development using an aldehyde condensation reaction. 
4 
While quantifying the diversity of a transient library is 
often difficult, HPLC-MS of a small library consisting of five 
(A4, A5, A8, A15, and A22) aldehydes (Figure 1) following 
reduction showed molecular ions representing the mono- and 
di-substituted derivatives; indicating that each of the proposed 
species was forming in the library (Figure 2).  
Even as HPLC-MS of the small sample 
library showed the detection of the proposed species, analysis of the library upon exposure to a 
template (neuraminidase enzyme in this case) is often 
complex and difficult to quantify. In order to 
overcome this problem a “virtual library”, or library 
where the individual components cannot be detected 
unless amplified by the presence of a template, was 
utilized. By having only trace amounts of the library 
members present only those substrates that bind to the 
template and are amplified as a result will be 
detected. Upon addition of the neuraminidase 
extracellular domain to the library (1:1 ratio in 
respect to the amine scaffold), a significant shift in the library composition was detected using 
HPLC-MS favoring condensation products with larger hydrophobic side-chains (A22, A13, and 
A8) (Figure 3) where A# represents the various aldehydes utilized). As the concentration of the 
library members was extremely low, only amplification of the condensation product with 
Figure 2. HPLC-MS analysis of sample 
library.12 Copyright 2002 National Academy of Sciences, 
USA. 
Figure 1. Selected sample library aldehydes. 
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aldehyde A22 could be quantified and was found to be amplified 120-fold in the presence of the 
neuraminidase enzyme (as compared to the absence of the neuraminidase). Since a “virtual 
library” was being utilized the detection of the condensation substrates strongly suggests that a 
binding interaction with the enzyme had occurred and led to amplification of the substrates. 
Synthesis and isolation of library hits 11, 12, and 13 (Figure 3) showed that 11 and 12 possessed 
considerably higher Ki values (2.16 and 1.64 µM, respectively) than the initial amine scaffold 
(31.3 µM) while 13 only showed a slightly lower Ki value (22.7 µM). The significantly better Ki 
values of library hits 11and 12 further supports that the neuraminidase had bound to the 
substrates of the dynamic library and caused the subsequent amplification and detection.  
Scheme 3. Model Diels-Alder reaction. 
Figure 3. Observed library amplification.12 Copyright 2002 
National Academy of Sciences, USA. 
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In their efforts to identify a potential catalyst for the Diels-Alder reaction shown in 
Scheme 3, members of the Sanders group elected to explore a disulfide dynamic combinatorial 
library.13 Exposure of the Diels-Alder product to a dynamic combinatorial library of disulfides 
resulted in a 6.5 fold amplification of macrocyclic structures A and B (Figure 4). After isolation 
of the macrocycles, the group found that while macrocycle B bound tightly to the starting 
material it provided no catalytic activity. However, A bound strongly to the product and 
demonstrated a moderate increase in the rate of reaction. While the increase in reaction rate was 
modest, the potential use of a dynamic combinatorial library to identify novel catalytic systems 
was demonstrated. Others have gone on to employ similar methods to identify potential catalysts 
and have met with good success.14-15 While there have been many examples of applying dynamic 
combinatorial chemistry to the discovery of potential targets, one of the main problems in the 
field is the lack of viable reversible reactions that may be utilized.  
In an effort to increase the number of viable reversible reactions that may be utilized for 
the development of dynamic combinatorial libraries, the Wipf group designed a reversible 
thiazolidine exchange reaction (Scheme 4) that employs mild acetate-buffered conditions (pH 4, 
Figure 4. Macrocyclic catalysts from a dynamic combinatorial library. 
Scheme 4. Reversible thiazolidine exchange. 
 
7 
rt).16 The exchange reaction was then applied to the synthesis of a small “proof of concept” 
dynamic combinatorial library utilizing the thiazolidine scaffold under similarly buffered 
condtions. (Scheme 5). 
Additionally, the thiazolidine scaffold could be modified to provide a new oxazolidine 
substrate (Scheme 6) that could participate in a similar exchange reaction under acid-catalyzed 
conditions, providing an additional thermodynamically controlled reaction that may be applied in 
the development of a dynamic combinatorial library. 
In addition to developing a reversible thiazolidine reaction, the Wipf group has also 
utilized a pyrazolotriazinone scaffold in the generation of a small dynamic combinatorial 
library.17 Condensing a hydrazide scaffold with a number of aldehydes afforded several new 
pyrazolotriazinone derivatives (Scheme 7). 
Scheme 5. Thiazolidine dynamic library development. 
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Using conditions similar to those employed in the thiazolidine exchange reaction (pH 4 
buffer, 40 °C), an efficient exchange reaction using the pyrazolotriazninone substrate was then 
developed. Exposure of the pyrazolotriazinone to the exchange conditions in the presence of 
several aldehydes resulted in the creation of a small dynamic combinatorial library (Scheme 8). 
Building on work previously completed in our group, we hoped to apply similar chemistry in the 
development of a dynamic combinatorial library using pyrrolo[1,3]-diazepines. 
1.2 RESULTS AND DISCUSSION 
Our work began with the construction of the pyrrolo[1,3]-diazepine core using chemistry 
previously established in our group.18-19 The intermediate oxazolinone 1.1 was synthesized in a 
“3-component, 1-pot reaction” using 1-benzyl-3-piperidone, ethyl cyanoformate, and thiophenol 
(Scheme 9). Initial conditions using catalytic TiCl4 and BF3-etherate were found to afford the 
desired oxazolinone albeit in low yield (14%), however, the use of silica gel was found to 
Scheme 8. Reversible exchange of the pyrazolotriazinone scaffold. 
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moderately increase the yield (43%).19 Heating 1.1 at 150 °C using microwave irradiation 
afforded diazepine 1.2 via a domino 1,3-dipolar cycloaddition and retro-Mannich cyclization in 
good yield.18 
Diazepine 1.2 was hydrolyzed using a mixture of acetic acid and water to afford amine 
1.3 in a respectable yield (Scheme 10).18 Utilizing previously developed conditions, amine 1.3 
was condensed with two acetals under acidic conditions to provide functionalized diazepines 1.4. 
and 1.5.20 
Alternatively it was found that diazepines 1.4 and 1.6 could be synthesized using the 
corresponding aldehydes under comparable conditions although in slightly lower yields (Scheme 
11) While the yields are modest, these initial results were suggested the possibility of developing
the aldehyde “exchange reaction” into a dynamic combinatorial library. However, before 
developing our exchange chemistry we sought to functionalize the diazepine scaffold.  
NBn
O
SH
EtO CN
O
+
SiO2
C6H5CF3
24 h, 60 °C
43%
NBn
ON
PhS O
BnN
N
PhS
CO2Me
CO2Me
cat. Et2NH, TiCl4
BF3·Et2O
µW, 80 °C, 15 min
14% DMAD
µW, 150 ºC
10 min
70-80%
1.1 1.2
Scheme 9. Synthesis of the pyrrolo[1,3]-diazepine core. 
Scheme 10. Hydrolysis and acetal recyclization using the diazepine core. 
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In an effort to alter the electronics and sterics of the diazepine core, we sought to remove 
the thiophenol fragment and reduce the remaining pyrrole esters. Initial attempts to remove the 
thiophenol functionality using Raney-Ni afforded only trace amounts of the desired product 
(Table 1, Entry 1). The use of increased amounts of Raney-Ni (Table 1, Entry 2) provided 1.7 in 
20% yield. Changing the solvent from EtOH to THF improved the yield considerably (69%), 
(Table 1, Entry 3) . Lowering the reaction temperature to 0 °C was found to increase the yield of 
1.7 to 92% (Table 1, Entries 4-5). With the desulfurized material in hand we next investigated 
the ester reduction.  
We initially found that the use of tBu2AlH at low temperature provided the desired diol in 
moderate yield (44%) while LiBH4 was not reactive (Table 2, Entries 1-2). Fortunately, the use 
Scheme 11. Aldehyde condensation using the diazepine core. 
Table 1. Desulfurization of the Diazepine Core 
11 
of excess Red-Al afforded diol 1.8 
quantitatively (Scheme 12). Furthermore, 
diazepine 1.2 could be reduced under the 
same conditions to afford diol 1.9 (Scheme 
12). 
We then investigated the 
propensity of the reduced diazepine 
derivatives toward hydrolysis and 
cyclization using conditions similar to those previously employed. Diazepine 1.7 was hydrolyzed 
more rapidly than the parent diazepine (1.2) and afforded the desired amine 1.10 in a respectable 
yield (61%) (Scheme 13). The resulting amine 
was condensed with benzaldehyde and supplied 
the diazepine 1.11 in moderate yield. Removal 
of the thiophenol portion appears to increase the 
reactivity of the amine species towards condensation 
and may be the result of decreased steric strain.  
Looking to further investigate the application of the hydrolysis and aldehyde 
condensation reaction, we attempted the hydrolysis of diol 1.8 (Scheme 14). Whereas 
desulfurized diazepine 1.7 was efficiently hydrolyzed, diol 1.8 was found to decompose under 
Scheme 13. Hydrolysis and recyclization of diazepine 1.7. 
Table 2. Pyrrole Ester Reduction 
Scheme 12. Reduction of diazepine 1.2. 
12 
the hydrolysis conditions and amine 1.11 was not observed. The increase of pyrrole electron 
density following ester reduction may lead to increased rates of undesired oxidative side-
products and results in the decomposition of the material.21 
Having demonstrated the ability to hydrolyze and condense amine intermediates 1.3 and 
1.9 with several aldehydes we next sought to develop conditions that would be suitable for a 
reversible, thermodynamically-controlled, aldehyde “dynamic exchange reaction” that could be 
used in the creation of a dynamic combinatorial library (Table 3). Initially, we hoped to utilize 
mild, buffered conditions, unfortunately, after investigating several different buffered systems 
Scheme 14. Hydrolysis of diol 1.8. 
Table 3. Dynamic Exchange of Pyrrolo[1,3]-Diazepines 
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(Table 3, Entries 1-3) we found that more vigorous conditions would be necessary. We next 
pursued the use of several different strong acids (Table 3, Entries 4-7).  
While the starting material was found to hydrolyze under these conditions, the recyclized 
product was not observed. Conditions similar to those initially used for the hydrolysis of the 
diazepine core (Table 3, Entries 10-11) provided efficient hydrolysis, however, formation of 
diazepine 1.4 was not observed. Utilizing the same conditions previously used for the cyclization 
of the hydrolyzed amine intermediate (Table 3, Entry 12) provided the amine intermediate with a 
trace of the desired product. 
In order to better understand the thermodynamics of our proposed dynamic exchange 
process, the heat of formation of each reaction component was calculated using Scigress 
(Scheme 15).22 The hydrolysis of 1.2 to 1.3 was found to require 6.0 kcal/mol while the 
recyclization of 1.3 to 1.4 would require 3.8 kcal/mol (the heat of formation values for H2O, 
CH2O, and PhCHO were -58.1, -38.4, and -15.4 kcal/mol, respectively). The overall exchange 
process (1.2 to 1.4) should then require an overall 9.8 kcal/mol; indicating that the each 
individual step is endothermic as is the overall exchange reaction. While heat of formation 
calculations suggest that both the hydrolysis and recyclization steps are endothermic and that the 
hydrolysis is in fact less thermodynamically favorable our experimental data indicates that the 
hydrolysis is likely more facile than the recyclization. One possible rationalization is that the 
heat of formation calculation does not take into account the entropic effects that the hydrolysis 
Scheme 15. Heat of formation comparison. 
14 
and recyclization of the diazepine ring entails. Hydrolysis of the ring system should result in an 
increase in the degrees of rotational freedom of the system and thus be entropically favorable 
whereas recyclization of 1.3 would likely be entropically unfavorable. 
1.3 CONCLUSIONS 
In our efforts toward the development of a dynamic combinatorial library using 
pyrrolo[1,3]-diazepines, we have shown the potential to hydrolyze and recyclize the diazepine 
core via the condensation of several different aldehydes to afford novel diazepine derivatives. 
Additionally, we have been able to modulate the electronics and sterics of the core through the 
removal of the thiophenol and reduction of the pyrrole esters. Our work towards finding suitable 
conditions for a thermodynamically controlled dynamic exchange reaction have shown that 
while hydrolysis of the diazepine core is possible, recyclization of the resulting amine 
intermediate appears to be unfavored. 
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2.0  DEVELOPMENT OF NOVEL POXVIRUS RESOLVASE INHIBITORS 
2.1 INTRODUCTION 
2.1.1 Poxvirus: A Bioterrorism Threat? 
The poxvirus is estimated to be responsible for 300-500 million deaths during the 19th 
century alone, killing more people than every war combined.23-24 The disease typically presents 
with high fever, muscle pain, and malaise, eventually leading to a maculopapular rash resulting 
in raised, fluid-filled blisters.25 Historically, the virus has had a 30% fatality rate although the 
values vary depending on the subtype of the disease.25 The poxvirus, or variola virus, exists in 
two major forms with the most common and deadly being the variola major. Fortunately, the 
virus was officially eradicated in 1980 due in most part to the creation of the poxvirus vaccine. 
Despite this proclamation the employment of the virus as a biochemical weapon has remained a 
significant risk.  
One of the earliest examples of biochemical warfare using the poxvirus occurred during 
the siege of Fort Pitt in 1763 when contaminated blankets were used to infect the fort’s 
occupants.26 The first serious threat however did not occur until 1947 when the then Soviet 
16 
Union established a small chemical weapons factory designed to weaponize the virus.27 In 1992, 
reports surfaced that the Soviet Union had successfully weaponized a “large-stockpile” of the 
virus posing a significant bioterrorism threat.28 Russia has reportedly destroyed all but a few 
remaining samples of the virus, which are used strictly for research purposes.  Subsequently, 
several reports have surfaced of the poxvirus being weaponized, however, there has been no 
evidence validating those stories. 
The CDC has declared the poxvirus a “Category A” bioterrorism threat for the following 
reasons: “it can be easily spread or transmitted from person to person, it results in high death 
rates and has the potential for major public health impact, it may cause public panic and social 
disruption, and it requires special action for public health preparedness”.29 While the remaining 
sources of the virus are securely stored in laboratories found in the United States and Russia, the 
possibility of a terrorist attack using the poxvirus remains a grave threat.24 As an increasing 
percentage of today’s population has not been vaccinated against the virus, an attack could be 
devastating and has become a grim concern following recent terroristic attacks. 
Although a poxvirus vaccine is available, the incubation period of the virus is 9-17 days 
whereas the vaccine typically must be administrated within 4 days of innoculation in order to be 
effective.24 Additionally, the overall effectiveness of the vaccine has often been brought into 
question and implores that an alternative solution be found. After the 
terroristic attacks in 2001 the U.S. initiated an effort to generate 
large stockpiles of drugs and vaccines that could be utilized in 
response to a biochemical attack. Until very recently there 
has not been a suitable drug for the treatment of the 
poxvirus.24 Fortunately, Siga Technologies® has begun the production of ST-246®, the first 
N
O
O N
H
O
CF3
Figure 5. ST-246 (Tecovirimat).
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small molecule antiviral found to effectively inhibit the poxvirus via the disruption of viral 
packaging (Figure 5).30 While the compound has yet to obtain FDA consent, officials expect the 
drug to receive approval within the next 5 years and become commercially available shortly 
thereafter. Even as the production of ST-246 has started, viral mutation and resistance 
necessitates the availability of multiple alternative treatments.31  
2.1.2 Poxvirus Activity and Possible Therapeutic Targets 
Efforts to find an effective inhibitor of the poxvirus have led to the discovery of several 
potential therapeutic targets, many of which focus on the replication of viral DNA. One 
consideration while evaluating potential therapeutic targets is that poxvirus DNA replication 
occurs entirely within the host cell and many of the required replication proteins are encoded 
within the viral genome.32  
One of the recent targets of interest has been the vaccinia virus processivity factor (PF) 
complex consisting of the E9 polymerase33-34, A20 processivity factor35, and D4 uracil DNA 
glycosylase.36-38 The vaccinia virus, which was used to create the poxvirus vaccine, is an ideal 
surrogate for the variola virus due to its high sequence homology as well as improved 
experimental properties (i.e. solubility).37 Although, the exact roles of A20 and D4 have not yet 
been determined, both appear to be necessary for efficient DNA replication and have been 
evaluated as potential anti-viral targets.36-38 
A high-throughput screening campaign of 28,000 compounds afforded 5 compounds 
(Figure 6) that demonstrated reduced viral plaque growth with low cytotoxicity.37 These 5 hits all 
showed D4 binding but only 3 showed significant reduction of viral DNA replication, indicating 
that while all of the compounds affected viral growth only 3 did so via the inhibition of DNA 
18 
replication. Molecular docking 
to the D4 glycosylase 
subsequently showed that all 5 
substrates interacted with 
amino acids K126, K160, and 
R187, which were previously 
shown to be critical for D4 
activity.36 Protein mutations 
often create resistant viral 
strains that counteract the 
effect of anti-viral treatments and have lead to the use of “cocktails” or combinations of multiple 
anti-viral drugs in order to combat the infection. Thus, having a variety of potential anti-viral 
drugs provides alternative treatments for patients with resistant viral strains. However, an 
alternative method that may avoid viral mutations is the inhibition of the host cell enzymes that 
are necessary for viral replication.  
A new series of potential targets has been the Abl-family of 
tyrosine kinases found within viral host cells.39-40 In 2005, STI-571 
(Gleevac), a known Abl-family tyrosine kinase inhibitor normally 
used in the treatment of chronic myelogenous 
leukemias, was found to drastically reduce viral 
levels (Figure 7).40 The Src- and Abl-family kinases were found to be essential for actin motility 
and release of extracellular enveloped virus (EEV). In this approach, inhibition of the host 
machinery (Abl-kinase) using STI-571 blocked viral replication. This method is interesting in 
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that disrupting the host proteins necessary for the viral life cycle bypasses the possibility of viral 
mutations that may negate the effects of anti-viral medication while hopefully not affecting the 
host cell itself.40 However, a significant concern with this type of approach is the possible 
cytotoxicity the drugs may possess. In addition to the use of STI-571 in the inhibition of EEV 
release, the promising anti-viral ST-246 appears to also target viral packaging.  
ST-246 (Tecovirimat) was initially discovered as part of a high-throughput screening 
effort initiated in 2002.41 A series of tricyclononene carboxamides were discovered within the 
group of 759 hits from 356,240 compounds. SAR studies of the scaffold resulted in the synthesis 
of ST-246 which possessed an EC50 of 0.04 µM.41 Genetic resistance mapping revealed the 
vaccinia F13L gene, which participates in the wrapping of intracellular mature virus, to encode 
the target of ST-246. Compound ST-246 is believed to block the interaction of p37, a protein 
encoded by F13L, with Rab9 and TIP47.41 Rab9, TIP47, and p37 form a wrapping complex 
necessary for the packaging of intracellular mature virus particles. While ST-246 still seeks FDA 
approval, other anti-viral agents are still desired.  
An additional target that has been gaining more attention over the last 5 years has been 
the poxvirus resolvase. The resolvase enzyme belongs to the RNase H superfamily of enzymes, 
which also includes HIV-I integrase.42-43 The resolvase enzyme has been recognized as a critical 
enzyme required for viral DNA replication.44 The poxvirus replicates via a “rolling hairpin” 
mechanism resulting in a linear concatemer genome (Figure 8).45-46 Inverted repeat sequences in 
the linear genome form cruciform structures known as Holliday junctions.47 Holliday junctions 
are formed during the crossover and recombination of two double-stranded DNA molecules. The 
junctions are known to occur in many different bacteria and viruses and play a critical role in 
genetic replication.48 The resolvase enzyme is highly selective for Holliday junctions and cleaves 
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the cruciform structures into monomeric DNA fragments. Ligation of the resulting fragments 
affords the characteristic DNA hairpins associated with the poxviruses. Previous work has shown 
that the inactivation of the resolvase enzyme results in the accumulation of uncleaved DNA and 
arrest of viral DNA synthesis; indicating that the resolvase is critical for viral DNA replication in 
vivo.44 Thus, inhibition of the poxvirus resolvase has been shown to prevent viral DNA 
replication and provides an intriguing therapeutic target. 
While the resolvase enzyme has been recognized as a potential therapeutic target much is 
still unknown about its exact structure and mechanism. Fortunately, HIV-I integrase, which also 
belongs to the RNase H superfamily of enzymes, shares a great deal of homology with the 
poxvirus resolvase and has been studied more thoroughly. As a result, many of the potential 
inhibitors and strategies applied to the HIV integrase are also applicable to the resolvase enzyme.  
The active site of the HIV-I integrase requires divalent metals, usually Mg2+ or Mn2+, for 
activity.49 The integrase activity is controlled by a set of essential acidic amino acids known as 
Figure 8. Cleavage of the Holliday junction by the poxvirus. 
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the DDE motif (D64, D116, and E152) that chelate these metals.49 The DDE motif is highly 
conserved over the RNase H superfamily and very similar motifs are found in the poxvirus 
resolvase. Studies have also demonstrated the presence of divalent metals (Mg2+) in the 
enzymatic active site of the fowlpox resolvase.43, 50 The metals are surrounded by 5 key acidic 
amino acids: D7, E60, K102, D132, and D135, resembling the DDE motif found in the HIV 
integrase.42 Removal of these amino acid residues or the metals themselves resulted in the 
elimination of enzymatic activity, emphasizing the necessity of the DDE scaffold and active site 
metals. 
Many of the current HIV-I integrase and RNase H inhibitor designs have focused on the 
ability to chelate the active site metals (Mg2+) that are required for enzymatic activity. A 
common motif of 3 aligned heteroatoms (highlighted in red) is often observed in many of the 
potential metal-chelating inhibitors (Figure 9) as activity has been found to correlate to the 
ability of the inhibitor to bind to two Mg2+ atoms separated by 3.6-4.0 Å.49 Some of the most 
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relevant scaffolds have been the di-keto acid (L-708,906-integrase and RNase H inhibitor)51-52, 
8-hydroxyquinoline-7-carboxamide (L-870,810-integrase inhibitor)53, 6-hydroxy-5-
oxopyrimidinecarboxamide (Raltegravir-integrase inhibitor)54, and 2-hydroxyisoquinoline-
1,3(2H,4H)-dione moieties (RNase H inhibitor).55 The di-keto acid moiety has been repeatedly 
shown to exhibit activity against the HIV integrase enzyme and presents an interesting structure 
to incorporate into future work.49, 56-58 
Several di-keto acid containing 
scaffolds demonstrate HIV-integrase in 
vitro and in vivo inhibition (IC50 50-400 
nm) through this active site metal-
chelation mechanism (Figure 10). 
Specifically, the inhibitors are 
thought to interrupt the strand 
transfer process of HIV-I integrase and as a result inhibit viral DNA replication.49 However, 
removal or modification of the di-keto acid scaffold significantly decreases inhibition (IC50  
>100,000 nm) of the strand transfer process (Figure 11).  
Related work has supported the hypothesis that di-keto acid inhibitors coordinate with the 
Mg2+ found in the integrase active site.59 Figure 12 displays the modeled binding interactions of 
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the known HIV-I integrase inhibitors L-731,988 (A), L-708,906 (B), and S-1360 (C).49, 60 
Importantly, the di-keto acid moiety is found to chelate the active site Mg2+ (highlighted by the 
red arrow) in each example. Similar interactions between the di-keto acid scaffold and metals 
found in the active site of the poxvirus resolvase are expected due to the structural similarities 
between the integrase and resolvase, lending to the idea that proposed HIV-I integrase inhibitors 
and strategies should be applicable to the resolvase enzyme. 
Figure 12. Binding interactions of L-731,988 (A), L-708,906 (B), and S-1360 (C).58 Reproduced with 
permission from Elsevier 
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The di-keto acid moiety has also been incorporated into other potential HIV integrase 
inhibitors. Efforts toward the discovery of new di-keto acid inhibitors resulted in the discovery of 
the novel nucleobase di-keto acid shown in Figure 14.47 The acid was found to possess an IC50 
BnN
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Figure 14. Nucleobase HIV integrase inhibitor. 
Figure 13. Molecular docking of nucleobase diketoacid to HIV-1 integrase.46
Reproduced with permission from Elsevier 
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value of 50 nM in vivo while FDA-approved HIV reverse transcriptase inhibitor AZT (Retrovir) 
demonstrated an IC50 value of 0.14 nM in similar control assays. Molecular docking of the 
nucleobase inhibitor to HIV-I integrase (Figure 13) strongly suggests that the uracil amide 
carbonyl (4-position) participates with the di-keto acid functionality in the chelation of the Mg2+ 
found in the enzyme active site. We elected to use the nucleobase di-keto acid scaffold as a 
starting point for the development of similar di-keto acid substrates utilizing a pyrimidinone 
core. 
Focusing on the previously disclosed nucleobase scaffold we propose the incorporation 
of the di-keto acid and other known chelating functionalities into a pyrimidinone-based scaffold 
(Figure 15). Based on the predicted overlap between the known nucleobase inhibitor and our 
proposed di-keto acid, we anticipate the possible participation of the pyrimidinone carbonyl in 
the chelation of the active site metal; similar to the uracil binding mechanism proposed in the 
docking simlulation of the nucleobase scaffold (Figure 15). 
Figure 15. Proposed mode of chelation. 
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Our work began with the construction of the pyrimidinone core utilizing the Biginelli 
reaction. This multi-component process provided pyrimidinones 2.1-2.9 in good to high yields 
(Table 4).61-62 Electronic and stereochemical diversity was provided via the incorporation of 
several different aldehydes while additional diversity was also introduced using differently 
substituted ureas. This approach not only provides the desired substituted heterocycles in high 
yield, but also incorporates opportunities for further manipulation and diversification.  
With the pyrimidinone core in hand, we attempted to install the α,γ-diketoacid chelating 
moiety (Scheme 16). Acetylation of 2.1 at the N3-position went smoothly and quantitatively 
afforded pyrimidinone 2.10.63 Treatment of 2.10 with LiHMDS and dimethyl oxalic acid did not 
afford the desired α-hydroxyester.56, 64 At this point, we elected a different method to install the 
chelating moiety using acetonide 2.13. 
Scheme 16. Introduction of α,γ-diketoacid moiety. 
Table 4. Pyrimidinone Synthesis via the Biginelli Reaction 
2.2 RESULTS AND DISCUSSION 
27 
The synthesis of acetonide 2.13 began with the acetalization of L-tartaric acid in the 
presence of 2,2-dimethoxypropane and catalytic BF3OEt2 (Scheme 17).57 Preparation of the 
carboxylic acid was completed using sodium tert-butoxide in THF to afford the desired 
compound in good yield (69%). With this acetonide-coupling fragment in hand we next sought 
methods to combine the acetonide with the pyrimidinone scaffolds.  
Our initial attempts focused on the conversion to acid chloride 2.14 using oxalyl chloride 
and catalytic DMF (Scheme 18). Crude acid chloride 2.14 was directly used in the following 
coupling step without further purification.57-58 Treatment of pyrimidinone 2.1 with nBuLi at low 
temperature followed by the crude acid chloride led to mixed results with only trace amounts of 
the desired product 2.15 and un-reacted starting material. However, the incorporation of catalytic 
pyridine and elongated reaction times led to a mixture of starting material, coupled product, and 
a dimeric species resulting from the nucleophilic opening of the acetonide system. Using CH2Cl2 
as the solvent (Table 5, Entry 3) gave a 1:1 mixture of starting material and the desired product, 
as determined by LC-HRMS. Surprisingly, the use of DMAP and Et3N in place of pyridine and 
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Scheme 17. Synthesis of acetonide fragment 2.13 
Scheme 18. Coupling with acid chloride 2.14. 
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nBuLi also led to a 1:1 mixture of starting material and the desired coupled product (Table 5, 
Entry 4).  
As a result of the amide 
formation in the absence of strong 
base, a coupling strategy using the 
carboxylic acid was investigated. 
Acetonide 2.13 has been shown to 
participate in “amino acid-like 
couplings” with simplified 
substrates.57-58 This coupling most 
often employs the BOP reagent, but 
we opted to use T3P as the reagent has demonstrated high yields in a number of difficult amino 
acid-like couplings.58, 65-66 While others have reported coupling reactions using acetonide 2.13, to 
the best of our knowledge no one has reported using a substrate as complex as our pyrimidinone 
scaffold.58  
Table 5. Optimized Acid Chloride Coupling
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T3P (1.2 equiv.), acid (1.0 equiv.), DMAP (0.2 equiv.), 
Et3N (5.0 equiv.), CH2Cl2, rt, 72 h
T3P (2.2 equiv.), acid (2.0 equiv.), DMAP (0.4 equiv.), 
Et3N (5.0 equiv.), CH2Cl2, rt, 48 h
1:1 pdt:sm
82:18 pdt:sm
24% isolated
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nBuLi (1.1 equiv.), 
THF, 1 h, -78 ºC1 trace pdt.
2 nBuLi (1.1 equiv.), pyridine (0.2 equiv.), THF, -78 ºC- rt, overnight
2:2:1 
sm:pdt:dimer
3
DMAP (0.2 equiv.), Et3N (5.0 equiv.),
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4
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* Ratios determined by LC-HRMS
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Table 6. Acetonide Coupling Using T3P 
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Much to our delight, application of the typical amino acid coupling conditions using T3P, 
DMAP, and Et3N gave a 1:1 mixture of the desired acetylation product and un-reacted 
pyrimidinone (Table 6, Entry 1). Increasing the amount of T3P, DMAP, and carboxylic acid 
drastically increased the overall conversion (Table 6, Entry 2). Elongated reaction time (72 h) did 
not have a significant effect on the
reaction (Table 6, Entry 3). 
Although high reaction 
conversions were observed, 
only modest isolated yields 
were obtained due to difficult 
chromatographic purifications. 
In order to reduce the 
reaction time while also 
improving the overall reaction 
conversion, we investigated the use of microwave irradiation conditions (Table 7). An 86% 
conversion was obtained when the reaction was performed in CH2Cl2 at room temperature for 22 
h using pyrimidinone 2.2 (Table 7, Entry 
1). However, subjection of the reaction 
mixture to microwave irradiation at 100 
°C in ethyl acetate for 1 h afforded the 
acetylation product 2.16 in 90% 
conversion (40% isolated yield) and 
similar results were observed when 
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Scheme 19. Synthesis of acetonide 2.17. 
30 
using DMF as the solvent (Table 7, Entries 2-3). Using the optimized conditions (Table 7, Entry 
2), pyrimidinone 2.3 was used in the synthesis of acetonide 2.17 in 61% yield (Scheme 19). 
With the masked α,γ-diketoacid moiety in hand, we sought to saponify the acetonide to 
reveal the chelating portion of the molecule  (Scheme 20). Exposure of acetonide 2.15 to 
saponification conditions (1 M NaOH, THF) that were previously successful for analogous 
susbstrates resulted in the full consumption of the starting material and the desired di-keto acid 
as determined by LC-HRMS analysis. It became apparent, however, that isolation of the desired 
carboxylic acid would be problematic due to the instability of the desired carboxylic acid.57-58 
During extraction of the carboxylic acid using 1 M HCl(aq), the di-keto acid moiety is hydrolyzed 
to afford pyrimidinone 2.1. Additionally, the di-keto acid was found to decompose in a similar 
manner to the pyrimidinone core in a methanol solution as shown by LC-HRMS. Performing the 
reaction in MeCN also provided high conversions to the desired product but did not avoid the 
stability issue upon isolation attempts. Saponification attempts at low temperature (0 °C) resulted 
in incomplete conversion.  
We next switched to a slightly different set of reaction conditions (3:1 THF/H2O) 
recently reported in the literature used to saponify similar acetonide substrates.67 Utilizing the 
new conditions provided quantitative conversion of the acetonide, as determined by LC-HRMS, 
to the desired carboxylic acid; however, similar stability issues were observed. In order to reduce 
Scheme 20. Saponification of acetonide 2.15. 
31 
the amount of decomposition during extraction the crude reaction mixture was lyophilized to 
afford a mixture (84:16) of the sodium salt of acid 2.18 and pyrimidinone 2.1. In spite of this, the 
general stability of acid 2.18 became a great concern to us and we elected to modify the scaffold 
in order to avoid further stability issues. 
Observing that the acetylated pyrimidinone core 2.18 was generally unstable, we sought 
to incorporate a carbon spacer that would reduce the propensity of the di-keto acid towards 
hydrolysis. We began with the alkylation of pyrimidinone 2.1 and 2.19 to afford compounds 2.20 
and 2.22 (Scheme 21). Removal of the Boc-protecting group under traditional conditions (4 M 
HCl in dioxane) provided the hydrochloride salts 2.23 and 2.24 in excellent yield. Coupling of 
the acetonide fragment went smoothly and supplied acetonides 2.25 and 2.26. Saponification of 
acetonides 2.25 and 2.26 unmasked the desired di-keto acids 2.27 and 2.28 in high yield. It is 
important to note that while di-keto acid 2.18 was found to be labile in aqueous environments, 
derivatives 2.27 and 2.28 were more stable and were not hydrolyzed during the 1 M HCl 
workup. 
Scheme 21. Di-keto acid synthesis. 
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 In addition to incorporating a carbon linker, we questioned whether other known 
chelating functionalities (i.e. carboxylic acids, tetrazoles) could be incorporated into the 
pyrimidinone scaffold to provide biologically active compounds. We initially investigated the 
installation of simple carboxylic acids at the N3-position that could potentially chelate a metal ion 
with the assistance of the pyrimidinone core (Table 8). Alkylation using NaH and several bromo-
esters afforded compounds 2.29-2.33 in moderate to good yield, however, alkylation using the 
ethyl 4-bromobutanoate lower reactivity. Subsequent saponification of the resulting esters 
smoothly provided acids 2.34-2.38.  
Having prepared several carboxylic acid derivatives we next sought to incorporate 
tetrazoles into our pyrimidinone core (Table 9). Alkylation using using NaH afforded nitriles 
2.39-2.42 in moderate yield. As previously observed in the preparation of esters, alkyation using 
the longer 3-carbon linker bromide showed little reactivity. Formation of the tetrazole using 
TMSN3 and TBAF in THF afforded the desired products 2.43-2.45. 
Table 8.  Carboxylic Acid Derivative Synthesis 
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In addition to the installment of chelating functions at the N3-position we also sought to 
investigate the effect of moving the chelating groups to the N1-position of the pyrimidinone 
scaffold. Utilizing the corresponding carboxylic acid containing ureas in the Biginelli synthesis 
rapidly provided acids 2.46-2.48 (Scheme 22). One could envision similar chelating modes to 
those previously proposed although the actual active site binding could vary greatly with the 
chelating group residing at the N1-position. 
After synthesizing several substrates containing a carboxylic acid functionality at the N1-
position we became interested in replacing the urea moiety with a thiourea in order to study the 
possible effect on chelation (Scheme 23).68 Protection of thiourea using PMBCl afforded the 
hydrochloride salt 2.49 in excellent yield. Knoevenagel condensation of benzaldeyhde and 
methyl acetoacetate provided the desired enone 2.50 as an inconsequential mixture of Z and E 
Table 9. Tetrazole Derivative Synthesis 
Scheme 22. Installation of the N1-carboxylic acids. 
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isomers. Exposure of 2.49 and 2.50 to sodium acetate and mild heating afford the desired 
thiopyrimidine 2.51 as a mixture of isomers. 
With thiopyrimidine 2.51 in hand we next sought to alkylate at either the N1- or N3-
positions, as chelating functions would be desirable at both positions (Scheme 25). Alkylation 
using ethyl bromoacetate afforded 2.52 as a single regioisomer (N1-alkylation) in 76% yield 
while methyl 3-bromopropionate afforded the desired product (2.53) in 64% as a partially 
separable 4.4:1 mixture of regioisomers favoring the N1-product.  
Scheme 23. Thiopyrimidine synthesis. 
Scheme 24. Alkyation of thiopyrimidine 2.51 
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Exposure of 2.52 and 2.53 (single N1-isomer of each) to ethanethiol and TFA in CH2Cl2 
efficiently removed the PMB to reveal thioureas 2.54 and 2.55 (Scheme 24). Subsequent 
saponification afforded the desired carboxylic acids 2.56 and 2.57 in excellent yield.  
In addition to the compounds presented in this document, we elected to take advantage of 
our access to the large number of compounds present in the University of Pittsburgh’s center for 
Chemical Methodology and Library Development (CMLD). Based on our proposed chelation 
model we selected several compounds containing N1-carboxylic acids and varying pyrimidinone 
Scheme 25. Thiopyrimidine acid derivative synthesis. 
Figure 16. Selected CMLD substrates. 
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scaffolds for submission to biological testing in order to supplement our synthesized library 
(Figure 16). Biological testing was conducted by the Bushman group at the University of 
Pennsylvania and utilized a high-throughput fowlpox resolvase fluorescence polarization assay 
in which changes in fluorescence of a labeled Holliday junction were correlated to the cleavage 
of the junction by the fowlpox resolvase and could be used to determine resolvase activity.69 The 
biological data (Table 10) shows that substrates containing chelating functions at the N3-position, 
including esters, nitriles, carboxylic acids, and tetrazoles, showed no activity (IC50 > 300 µM). 
Furthermore, incorporation of the thiopyrimidine core did not afford active compounds. 
However, several of the compounds selected from the University of Pittsburgh CMLD 
possessing N1-carboxylic acids exhibited moderate inhibitory activity (IC50 16 µM). 
Surprisingly, compounds similar to MAL1-265, such as 2.46-2.48, did not show activity. Based 
on our initial data, the 4-position substitution of the pyrimidinone scaffold appears to play a 
critical role in binding and inhibitory activity. Further studies are underway to study the effect of 
Table 10. Biological Results 
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various carboxylic acid isosteres and 4-position substituents of the pyrimidinone. 
2.3 CONCLUSIONS 
In our efforts toward the development of a series of novel poxvirus resolvase inhibitors, a 
small library of new pyrimidinone-based small molecules have been synthesized utilizing the 
multi-component Biginelli reaction and submitted for biological testing. While our initial 
attempts to directly install the di-keto acid chelating functionality onto the pyrimidinone scaffold 
resulted in unstable products that were readily cleaved to afford the pyrimidinone core, the 
incorporation of an alkyl linker has improved the stability of the di-keto acids in aqueous 
environments. Additional chelating functionalities (i.e. carboxylic acids and tetrazoles) have also 
been utilized as potential substrates while we intend to also investigate other chelating groups. 
Initial biological data indicated that substrates containing chelating functions at the N3-position 
do not possess biological activity while moving the carboxylic acid function to the N1-position 
resulted in several substrates with moderate activity. The substitution at the 4-position of the 
pyrimidinone scaffold appears to be critical for activity, as slight changes result in the complete 
loss of activity based on our current data.  
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3.0  EXPERIMENTAL SECTION 
3.1 GENERAL 
All moisture sensitive reactions were performed using syringe-septum techniques under 
an atmosphere of either dry N2 or Ar unless otherwise noted. All glassware used in moisture 
sensitive reactions was flame-dried under an atmosphere of dry N2 or Ar prior to use. Dry 
tetrahydrofuran was purified by filtration through an activated alumina column or dried by 
distillation over sodium/benzophenone under a dry N2 atmosphere. Dry diethyl ether was 
purified by distillation over sodium/benzophenone under a dry N2 atmosphere. Dry methylene 
chloride was purified by filtration through an activated alumina column or by distillation from 
CaH2. All degassed solvents were prepared using the freeze/pump/thaw method (3x). Deuterated 
chloroform was filtered through an oven-dried alumina plug prior to use. Reactions were 
monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and 
visualized by using UV lamp (254 nm) and/or by staining with a ninhydrin solution (0.6 g 
ninhydrin in 6 mL acetic acid and 200 mL n-butyl alcohol) or a KMnO4 solution (3.0 g KMnO4, 
4.0 g K2CO3, in 200 mL H2O and 4 mL 5% NaOH). Flash column chromatography was 
performed with 40-63 µm silica gel (Silicycle). Microwave reactions were performed on a 
Biotage Initiator microwave reactor. Infrared spectra were measured on a Smiths Detection 
IdentifyIR FT-IR spectrometer (ATR). All NMR data was collected at room temperature in 
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CDCl3 on a 300, 400, or 500 MHz Bruker instrument. Chemical shifts (δ) are reported in parts 
per million (ppm) with internal CHCl3 (δ 7.26 ppm for 1H and 77.00 ppm for 13C), (CH3)2CO (δ 
2.05 ppm for 1H and 29.84 ppm for 13C), or (CH3)2SO (δ 2.50 ppm for 1H and 39.52 ppm for 
13C) as the reference. 1H NMR data are reported as follows: chemical shift, multiplicity (s = 
singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bm = broad 
multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, qd = quartet 
of doublets, sep = septet), integration, and coupling constant(s) (J) in Hertz (Hz). 
Heat of Formation Calculations: 
Heat of formation values were calculated using Scigress. Initial conformational 
minimization was conducted using a CONFLEX/MM3 (extensive search) minimization. Heat of 
formation was then calculated using a PM3 (H2O) method. All values are reported in kcal/mol. 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Chapter 1 Experimental 
 
 
 
7-Benzyl-3-(phenylthio)-1-oxa-4,7-diazaspiro[4,5]dec-7-en-2-one (1.1).18 To a solution 
of 1-benzyl-3-piperidone hydrochloride (376 mg, 1.60 mmol, 1.0 equiv) in water (3.1 mL, 0.5 
M) was added K2CO3 (335 mg, 2.42 mmol, 1.5 equiv). The reaction mixture was stirred at room 
temperature for 30 min and extracted with EtOAc (3 mL, 3x). The combined organic extracts 
NBn
ON
PhS O
1.1
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were dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum to 
afford 1-benzyl-3-piperidone (305 mg, 1.61 mmol, 97%). To a stirred solution of thiophenol 
(201 µL, 1.90 mmol, 1.2 equiv) in trifluorotoluene (1.9 mL, 1.0 M) in a flame-dried microwave 
vial under an Ar atmosphere at 0 °C was added ethyl cyanoformate (158 µL, 1.58 mmol, 1.0 
equiv). The reaction mixture was stirred for 2 h at room temperature, cooled to 0 °C, and SiO2 
(162 mg, 1.80 mmol, 1.1 equiv, 11.1 mmols/g) was added. After stirring for 10 min at 0 °C a 
solution of 1-benzyl-3-piperidone (305 mg, 1.61 mmol, 1.0 equiv) in trifluorotoluene (1.1 mL, 
1.4 M) was added drop-wise to afford a mild yellow solution, which was stirred at room 
temperature for 24.5 h. The reaction mixture purified using chromatography on SiO2 (4:1, 
hexanes/ethyl acetate, isocratic) to afford a crude light yellow oil residue. The resulting crude 
residue was purified further using recrystallization (ethyl acetate/hexanes) to afford 1.1 (246 mg, 
0.698 mmol, 43%) as a clear crystalline solid. Remaining crude material was recrystallized again 
to afford additional 1.1 (51.0 mg, 0.144 mmol, 9%) as a pale yellow crystalline solid (combined 
total yield of 52%): MP 92.4-97 °C; IR (neat) 2945, 2805, 1771, 1581, 1439, 1249, 1115, 1053, 
973, 738, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.62-7.57 (m, 2 H), 7.47-7.41 (m, 3 H), 7.34-
7.28 (m, 4 H), 7.28-7.23 (m, 1 H), 3.66, 3.56 (AB, 2 H, J = 13.5 Hz), 2.89-2.83 (m, 1 H), 2.55 (t, 
2 H, J = 13.5 Hz), 2.24 (t, 1 H, J = 10.4 Hz), 2.01-1.96 (m, 2 H), 1.81-1.75 (m, 1 H), 1.67-1.60 
(m, 1 H); 13C NMR (125 MHz, CDCl3) δ 162.7, 161.5, 137.7, 133.9, 129.8, 129.5, 128.8, 128.3, 
127.2, 126.4, 106.8, 61.9, 59.8, 52.1, 34.3, 22.1; HRMS (EI+) m/z calcd for C20H21N2O2S 
([M+H]+) 353.1324, found 353.1309. 
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Dimethyl-2-benzyl-8-(phenylthio)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-
c][1,3]diazepine-6,7-dicarboxylate (1.2).18 To a solution of 1.1 (409 mg, 1.16 mmol, 1.0 equiv) 
in chlorobenzene (2.3 mL, 0.5 M) was added dimethyl acetylenedicarboxylate (286 µL, 2.33 
mmol, 2.0 equiv) to afford a mild yellow solution that was heated at 150 °C for 10 min using 
microwave irradiation. The reaction mixture was directly purified using chromatography on SiO2 
(4:1, hexanes/ethyl acetate, isocratic) to afford a crude residue. The resulting residue was 
purified further using recrystallization (ethyl acetate) to 1.2 (267 mg, 0.593 mmol, 51%) as an 
off-white solid: MP 114.6-117.8 °C; IR (neat) 3027, 2937, 1722, 1702, 1581, 1493, 1450, 1212, 
118, 1077, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.31-7.18 (m, 3 H), 7.12-7.06 (m, 7 H), 5.12 
(s, 2 H), 3.85 (s, 3 H), 3.83 (s, 3 H), 3.39 (s, 3 H), 3.30 (bs, 2 H), 3.01 (t, 2 H, J = 5.0 Hz), 1.70-
1.65 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 166.1, 164.6, 143.6, 137.9, 136.3, 129.1, 128.4, 
127.2, 126.3, 125.2, 119.8, 111.4, 65.5, 54.4, 52.7, 52.3, 51.5, 25.5, 22.1; HRMS (EI+) m/z calcd 
for C25H25N2O4S ([M-H]+) 449.1535, found 449.1573. 
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Dimethyl-2-(3-(benzylamino)propyl)-5-(phenylthio)-1H-pyrrole-3,4-dicarboxylate 
(1.3).18 A solution of 1.2 (167 mg, 0.370 mmol, 1.0 equiv) in acetic acid (8.4 mL) and water (1.7 
mL) was heated at 95 °C for 48 h with stirring. The reaction mixture was concentrated under 
reduced pressure and purified using chromatography on SiO2 (9:1 CH2Cl2/MeOH, isocratic) to 
afford 1.3 (116 mg, 0.264 mmol, 71%) as a light tan solid: MP 108-110 °C; IR (neat) 3064, 
3000, 2951, 1737, 1700 1448, 1291 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.22-7.09 (m, 10 H), 
3.84 (s, 3 H), 3.77 (s, 3 H), 3.67 (s, 2 H), 2.95 (t, 2 H, J = 6.6 Hz), 2.59 (t, 2 H, J = 5.6 Hz), 1.99-
1.89 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 178.3, 166.1, 164.5, 140.8, 137.0, 132.9, 129.8, 
129.2, 129.1, 129.1, 128.1, 126.5, 124.8, 118.6, 111.9, 52.4, 52.0, 51.5, 45.8, 26.1, 23.9, 23.7, 
14.4. 
Dimethyl-2-benzyl-1-phenyl-8-(phenylthio)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-
c][1,3]diazepine-6,7-dicarboxylate (1.4).20 A solution of 1.2 (50.0 mg, 0.111 mmol, 1.0 equiv) 
in acetic acid (1.9 mL) and water (320 µL) was heated at 95 °C for 24 h. The reaction mixture 
was azeotropically dried using toluene (2 mL, 2x) and the resulting yellow oil residue was 
dissolved in toluene (2.2 mL). Pyridinium p-toluenesulfonate (33.0 mg, 0.131 mmol, 1.2 equiv) 
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and benzaldehyde (57.0 µL, 0.550 mmol, 5.0 equiv) was added followed by activated 4 Å 
molecular sieves. The reaction mixture was heated at reflux for 4 h, basified to a pH of 9-10 
using 0.5 M Na2CO3, and extracted using EtOAc (2 mL, 3x). The combined organic extracts 
were dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum to 
afford an opaque oil residue. The resulting crude residue was purified using chromatography on 
SiO2 (4:1, hexanes/ethyl acetate, isocratic) to afford 1.4 (33.0 mg, 0.0627 mmol, 56%) as an 
opaque, white solid: MP 162.2-165.2 °C; IR (neat) 3059, 2939, 1707, 1489, 1443, 1213, 1128, 
744 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.36-7.26 (m, 4 H), 7.18-7.14 (m, 3 H), 7.12-7.08 (m, 2 
H), 7.02-6.97 (m, 3 H), 6.97-6.92 (m, 1 H), 6.87-6.82 (m, 2 H), 3.90 (s, 3 H), 3.85 (s, 2 H), 3.62, 
3.56 (AB, 2 H, J = 14.5 Hz), 3.06 (t, 1 H, J = 14.3 Hz), 2.85 (d, 1 H, J = 15.0 Hz), 2.24 (t, 1 H, J 
= 13.9 Hz), 1.81 (q, 1 H, J = 13.5 Hz), 1.39-1.32 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 
166.3, 164.7, 143.3, 138.4, 136.3, 134.8, 129.1, 128.7, 128.4, 128.3, 127.6, 127.2, 126.7, 125.4, 
122.0, 111.9, 54.8, 52.3, 51.6, 47.3, 25.1, 21.3; HRMS (EI+) m/z calcd for C31H31N2O4S 
527.2005 ([M+H]+), found 527.2018. 
 
Compound 1.4 could also be prepared as follows: 
To a stirred solution of 1.2 (52.2 mg, 0.119 mmol, 1.0 equiv) in dry toluene (3 mL, 0.04 
M) was added pyridinium p-toluenesulfonate (34.8 mg, 0.138 mmol, 1.2 equiv) and methyl 4-
(dimethoxymethyl)benzoate (141 mg, 0.671 mmol, 5.6 equiv). All reagents were azeotropically 
dried using toluene prior to their addition. The reaction mixture was refluxed for 4 h, 
concentrated under reduced pressure, and dissolved in EtOAc (5 mL). The solution was basified 
to a pH of 9-10 using 0.5 M Na2CO3 and extracted using EtOAc (5 mL, 2x). The combined 
organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried using high 
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vacuum. The resulting crude residue was purified using chromatography on SiO2 (3:1, 
hexanes/ethyl acetate, isocratic) to afford 1.4 (57.4 mg, 0.084 mmol, 62%) as an light yellow 
crystalline solid: 1H NMR (300 MHz, CDCl3) δ 7.40-6.85 (m, 14 H), 3.97 (s, 3 H), 3.87 (s, 3 H), 
3.63 (AB, 2 H, J = 14 Hz), 3.03-2.86 (m, 2 H), 2.17 (t, 1 H, J = 15 Hz), 1.79 (q, 1 H, J = 11 Hz), 
1.40-1.34 (m, 1 H). Other data matched that previously obtained. 
 
 
 
 
 
Dimethyl-2-benzyl-1-(4-(methoxycarbonyl)phenyl)-8-(phenylthio)-2,3,4,5-
tetrahydro-1H-pyrrolo[1,2-c][1,3]diazepine-6,7-dicarboxylate (1.5).20 To a stirred solution     
of 1.3 (52.2 mg, 0.119 mmol, 1.0 equiv) in dry toluene (3 mL, 0.04 M) was added pyridinium p-
toluenesulfonate (34.8 mg, 0.138 mmol, 1.2 equiv) and methyl 4-formylbenzoate dimethyl acetal 
(141 mg, 0.671 mmol, 5.6 equiv). All reagents were azeotropically dried using toluene prior to 
their addition. The reaction mixture was refluxed for 4 h, concentrated under reduced pressure, 
and dissolved in EtOAc (5 mL). The solution was basified to a pH of 9-10 using 0.5 M Na2CO3 
and extracted with EtOAc (5 mL, 2x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and dried using high vacuum. The resulting crude residue 
was purified using chromatography on SiO2 (3:1, hexanes/ethyl acetate, isocratic) to afford 1.5 
(57.4 mg, 0.084 mmol, 62%) as an light yellow crystalline solid: IR (neat) 2932, 2951, 1726, 
1499, 1435, 1279, 1210, 1141, 1122, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.40-6.85 (m, 14 
H), 3.97 (s, 3 H), 3.87 (s, 3 H), 3.63 (AB, 2 H, J = 14 Hz), 3.03-2.86 (m, 2 H), 2.17 (t, 1 H, J = 
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15 Hz), 1.79 (q, 1 H, J = 11 Hz), 1.40-1.34 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.8, 
166.4, 141.8, 138.3, 134.7, 129.9, 129.7, 129.7, 129.0, 128.8, 128.7, 127.7, 127.0, 122.6, 52.6, 
52.4, 51.9, 48.0, 25.3, 21.5; HRMS (EI+) m/z calcd for C33H32N2O6SNa (M+Na+) 607.1879, 
found 607.1873. 
 
 
 
 
 
Dimethyl-2-benzyl-8-(phenylthio)-1-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydro-
1H-pyrrolo[1,2-c][1,3]diazepine-6,7-dicarboxylate (1.6). A solution of 1.2 (51.0 mg, 0.113 
mmol, 1.0 equiv) in acetic acid (1.9 mL) and water (320 µL) was heated at 95 °C for 23 h. The 
reaction mixture was azeotropically dried using toluene (2 mL, 2x) and the resulting yellow 
residue was dissolved in toluene (2.2 mL). Pyridinium p-toluenesulfonate (33.0 mg, 0.131 mmol, 
1.2 equiv) and 4-(trifluoromethyl)benzaldehyde (76.0 µL, 0.557 mmol, 4.9 equiv) was added 
followed by activated 4 Å molecular sieves. The reaction mixture was heated at reflux for 4 h, 
basified to a pH of 9-10 using 0.5 M Na2CO3, and extracted using EtOAc (2 mL, 3x). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried 
using high vacuum to afford an off-yellow residue. The resulting crude residue was purified 
using chromatography on SiO2 (4:1, hexanes/ethyl acetate, isocratic) to afford a yellow opaque 
residue which was purified further using recrystallization (hexanes) to 1.6 (21.7 mg, 0.0365 
mmol, 32%) as a white, flakey solid: MP 134.7-135.4 °C.; IR (neat) 3059, 2934, 1726, 1707, 
1491, 1446, 1320, 1228, 1141, 1124, 1066, 757, 701 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.38-
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7.29 (m, 6 H), 7.06-7.04 (m, 2 H), 6.99 (s, 1 H), 6.94-6.91 (m, 3 H), 6.91-6.86 (m, 2 H), 3.94-
3.91 (m, 1 H), 3.93 (s, 3 H), 3.86 (s, 3 H), 3.68, 3.62 (AB, 2 H, J = 14.0 Hz), 3.00-2.90 (m, 2 H), 
2.20-2.14 (m, 1 H), 1.86-1.79 (m, 1 H), 1.42-1.39 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 
166.2, 142.9, 138.0, 134.3, 129.9, 128.8, 128.6, 128.5, 127.5, 127.2, 127.1, 125.4, 122.6, 112.2, 
55.0, 52.5, 51.7, 48.1, 25.2, 21.4; HRMS (EI+) m/z calcd for C32H30N2O4F3S ([M]+) 594.1800, 
found 594.1835. 
Dimethyl-2-benzyl-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-c][1,3]diazepine-6,7-
dicarboxylate (1.7). To a solution of 1.2 (303 mg, 0.673 mmol, 1.0 equiv) in THF (2.1 mL, 0.3 
M) at 0 °C was added Raney-Nickel (5.55 g, 94.6 mmol, 140 equiv) in THF (10.5 mL) (the
Raney-Nickel was prepared from a 50/50 wt. suspension of Raney-Nickel in water after rinsing 
with THF (5 mL, 3x)). The reaction mixture was vigorously stirred at 0 °C for 4 h. The 
supernatant was removed and the remaining Raney-Nickel was rinsed with THF (5 mL, 3x). The 
combined organic extracts were concentrated under reduced pressure and dried using high 
vacuum to afford 1.7 (179 mg, 0.523 mmol, 78%) as a white solid: MP 99.8-101.6 °C; IR (neat) 
2937, 2852, 1685, 1530, 1441, 1208, 1120, 1062, 999, 727 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.37-7.30 (m, 2 H), 7.30-7.24 (m, 3 H), 6.91 (s, 1 H), 4.79 (s, 2 H), 3.86 (s, 3 H), 3.79 (s, 3 H), 
3.48 (s, 2 H), 3.21 (t, 2 H, J = 5.0 Hz), 3.09 (bs, 2 H), 1.88-1.80 (m, 2 H); 13C NMR (125 MHz, 
CDCl3) δ 166.0, 164.4, 139.7, 137.4, 128.7, 128.5, 127.5, 127.1, 113.4, 67.6, 56.9, 52.6, 51.6, 
51.3, 25.1, 23.3; HRMS (EI+) m/z calcd for C19H21N2O4 ([M-H]+) 341.1501, found 341.1521. 
BnN
N
CO2Me
CO2Me
1.7
 47 
 
 
 
 
 
(2-Benzyl-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-c][1,3]diazepine-6,7-diyl)dimethanol 
(1.8).    To a stirred solution 1.7 (19.8 mg, 0.0578 mmol, 1.0 equiv) in dry THF (2.9 mL, 0.02 M) 
under an Ar atmosphere at -10 °C was added Red-Al (23.0 µL, 0.118 mmol, 2.0 equiv). The 
reaction mixture was stirred at -10 °C for 2 h after which additional of Red-Al (23.0 µL, 0.118 
mmol, 2.0 equiv) was added. Additional Red-Al (69.0 µL, 0.354 mmol, 6.0 equiv) was added to 
the reaction mixture after 4 h and allowed to stir overnight after warming to room temperature. 
The reaction mixture was quenched via the addition of sat. Rochelle's salt solution (0.5 mL), 
stirred for 20 min, diluted with H2O (2 mL), and extracted with CH2Cl2 (2 mL, 3x). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried 
using high vacuum to afford 1.8 (16.5 mg, 0.0576 mmol, quant) as a fine white powder: MP  
107.9-109 °C; IR (neat) 3258, 2924, 2850, 1456, 1316, 1141, 977, 695 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.33-7.26 (m, 5 H), 6.37 (s, 1 H), 4.72 (s, 2 H), 4.58 (s, 2 H), 4.57 (s, 2 H), 3.47 
(s, 2 H), 3.20 (t, 2 H, J = 5 Hz), 2.82 (bs, 2 H), 2.49 (bs, 1 H), 2.40 (bs, 1 H), 1.72-1.68 (m, 2 H); 
13C NMR (125 MHz, CDCl3) δ 138.2, 132.8, 128.8, 128.4, 127.3, 120.4, 119.9, 119.0, 66.7, 57.5, 
57.1, 56.3, 52.6, 30.9, 24.7, 24.3; HRMS (EI+) m/z calcd for C17H23N2O2 287.1760, found 
287.1786. 
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(2-Benzyl-8-(phenylthio)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-c][1,3]diazepine-6,7-
diyl)dimethanol (1.19). To a solution of 1.2 (103 mg, 0.229 mmol, 1.0 equiv) in THF (11.1 mL, 
dry-solvent system, 0.02 M) at -10 °C was added sodium bis(2-
methoxyethoxy)aluminumhydride (0.430 mL, 2.21 mmol, 9.7 equiv) as a 70% w/w toluene 
solution. The reaction mixture was stirred at -10 °C for 5 min, warmed to room temperature 
overnight, and quenched by the slow addition of a sat. Rochelle's salt solution (4 mL) followed 
by water (4 mL). The resulting emulsion was stirred for 15 min and extracted using EtOAc (10 
mL, 3x). The combined organic extracts were washed with brine, dried (Na2SO4), concentrated 
under reduced pressure, and dried using high-vacuum to afford a crude residue. The resulting 
crude residue was purified using chromatography on SiO2 (ISCO-Rf, CH2Cl2/MeOH, 0-10% 
MeOH) to afford 1.9 (59.0 mg, 0.150 mmol, 65%) as a white foam: IR (neat) 3303, 3051, 2931, 
2850, 1581, 1467, 1435, 1316, 1215, 1053, 995, 820, 814, 738, 733, 695 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.31-7.23 (CDCl3 overlap, m, 3 H), 7.23-7.14 (m, 4 H), 7.09-7.02 (m, 1 H), 
6.95-6.88 (m, 2 H), 5.10 (s, 2 H), 4.75 (s, 2 H), 4.65 (s, 2 H), 3.40 (s, 2 H), 3.01 (t, 2 H, J = 5.1 
Hz), 2.95-2.85 (m, 2 H), 1.70-1.61 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 138.8, 138.4, 136.9, 
129.3, 129.0, 128.3, 127.0, 125.6, 125.4, 119.6, 115.5, 65.0, 57.3, 56.1, 54.6, 52.8, 30.9, 25.2, 
23.4; ; HRMS (EI+) m/z calcd for C23H27N2O5S ([M+H]+) 395.1788, found 395.1765. 
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3.2.2 Chapter 2 Experimental 
General Procedure A: Biginelli Substrate Synthesis7 
To a stirred solution of urea (1.0 equiv) in THF (0.2 M) under a N2 atmosphere was 
added aldehyde (2.0 equiv) and acetoacetate (2.0 equiv) sequentially. After stirring at room 
temperature for 5 min conc. HCl (0.7 equiv) was added drop-wise and the reaction mixture was 
stirred at room temperature for 24-72 h. The reaction mixture was concentrated under reduced 
pressure and resulting crude residue was recrystallized using a mixture of hexanes/ethyl acetate 
and/or t-butyl methyl ether to afford the desired pyrimidinone. 
 
General Procedure B: Acetonide Coupling 
To a mixture of pyrimidinone (1.0 equiv) in EtOAc (0.44 M) was added (Z)-2-(2,2-
dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid (2.0 equiv), T3P (2.2 equiv) as a  50% ethyl 
acetate solution, DMAP (0.4 equiv), and Et3N (5.0 equiv). The reaction mixture was heated at 
100 °C for 1 h in the microwave. 
 
 
 
 
Benzyl-1-benzyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2.1). According to General Procedure A, benzylurea (0.500 g, 3.26 mmol), 
benzaldehyde (576 µL, 6.56 mmol), benzyl acetoacetate (1.16 mL, 6.51 mmol), and conc. HCl 
(0.200 mL, 2.33 mmol) were stirred at room temperature for 72 h and provided a crude residue 
that was recrystallized using hexanes/ethyl acetate (1:1) and triturated using t-butyl methyl ether 
N
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to afford 2.1 (945 mg, 2.29 mmol, 70%) as a white solid:  MP 130-132 °C; IR (neat) 3227, 3115, 
3057, 3020, 2964, 1687, 1618, 1462, 1385, 1311, 1204, 1165, 1104, 1035, 958, 764, 725 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.30-7.24 (CDCl3 overlap, m, 9 H), 7.24-7.19 (m, 2 H), 7.15-7.13 
(m, 4 H), 5.48 (d, 1 H, J = 20.8 Hz), 5.45 (s, 1 H), 5.19, 4.91 (AB, 2 H, J = 16.2 Hz), 5.07, 5.05 
(AB, 2 H, J = 12.6 Hz), 2.47 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.7, 153.5, 149.8, 143.0, 
137.8, 135.9, 128.8, 128.7, 128.4, 128.1, 127.9, 127.2, 126.5, 126.4, 104.2, 66.1, 54.2, 16.6; 
HRMS (EI+) m/z calcd for C26H25N2O3 ([M+H]+) 413.1800, found 413.1855.  
Benzyl-1-benzyl-4-(4-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2.2). According to General Procedure A, benzylurea (501 mg, 3.27 mmol), 4-
chlorobenzaldehyde (927 mg, 6.53 mmol), benzyl acetoacetate (1.16 mL, 6.51 mmol) and conc. 
HCl (0.200 mL, 2.33 mmol) were stirred at room temperature for 67 h and provided a crude 
residue that was recrystallized using hexanes/ethyl acetate (1:2) to afford 2.2 (1.28 g, 2.86 mmol, 
87%) as a pale yellow powder: MP 171-173 °C; IR (neat) 3341, 3052, 3020, 1706, 1676, 1613, 
1393, 1311, 1215, 1197, 1154, 1104, 757, 720, 688 cm-1; 1H (400 MHz, CDCl3) δ 7.35-7.20 
(CDCl3 overlap, m, 6 H), 7.14-7.12 (m, 2 H), 7.12-7.08 (m, 6 H), 5.52 (d, 1 H, J = 10.4 Hz), 5.41 
(s, 1 H), 5.19, 4.89 (AB, 2 H, J = 16.6 Hz), 5.06, 5.02 (AB, 2 H, J = 12.6 Hz), 2.47 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 165.1, 152.7, 150.7, 142.7, 138.5, 136.2, 132.0, 128.5, 128.4, 128.3, 
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128.1, 127.8, 127.7, 126.9, 126.1, 102.5, 65.3, 51.9, 44.9, 16.0; HRMS (EI+) m/z calcd for 
C26H24ClN2O3 ([M+H]+) 447.9379, found 447.1465. 
(Note: this compound is commercially available from Aurora Screening Library, 
however, characterization data has yet to be published in the literature) 
 
 
 
 
 
 
Benzyl-1-benzyl-6-methyl-2-oxo-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.3). According to General Procedure A, benzylurea 
(251 mg, 1.64 mmol), 4-(trifluoromethyl)benzaldehyde (446 µL, 3.27 mmol), benzyl 
acetoacetate (557 µL, 3.26 mmol), and conc. HCl (0.100 mL, 1.17 mmol) were stirred at room 
temperature for 42 h and provided a crude residue that was recrystallized using hexanes/ethyl 
acetate (1:1) to afford 2.3 (0.640 g, 1.33 mmol, 81%) as a white solid: MP 177-179 °C; IR (neat) 
3216, 3102, 2975, 1706, 1687, 1631, 1324, 1210, 1165, 1109, 1066, 1040, 701 cm-1, 1H NMR 
(400 MHz, CDCl3) δ 7.48 (d, 2 H, J = 8.0 Hz), 7.32-7.23 (m, 8 H), 7.14-7.09 (m, 4 H), 5.61 (d, 1 
H, J = 21.2 Hz), 5.49 (d, 1 H, J = 3.2 Hz), 5.20, 4.88 (AB, 2 H, J = 16.6 Hz), 5.12, 5.02 (AB, 2 
H, J = 12.0 Hz), 2.49 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.4, 153.6, 150.5, 146.9, 137.6, 
135.6, 130.0 (d, J = 32.0 Hz), 128.7, 128.5, 128.2, 127.4, 126.4, 125.6 (t, J = 3 Hz), 124.0 (d, J = 
270.0 Hz), 103.7, 66.3, 53.5, 46.0, 16.6; HRMS (EI+) m/z calcd for C27H24N2O2F3 ([M+H]+) 
481.1700, found 481.1728. 
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Benzyl-1-benzyl-6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2.4). According to General Procedure A, benzylurea (502 mg, 3.28 mmol), p-
tolualdehyde (785 µL, 6.52 mmol), benzyl acetoacetate (1.16 mL, 6.51 mmol) and conc. HCl 
(0.200 mL, 2.33 mmol) were stirred at room temperature for 72 h and provided a crude residue 
that was recrystallized using hexanes/ethyl acetate (1:1) to afford 2.4 (1.02 g, 2.39 mmol, 73%) 
as a pale yellow powder: MP 170-172 °C; IR (neat) 3346, 3052, 3020, 1706, 1681, 1613, 1385, 
1316, 1191, 1160, 1109, 757, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.20 (m, 7 H), 7.16-
7.10 (m, 4 H), 7.10-7.06 (m, 4 H), 5.42 (bs, 2 H), 5.19, 4.92 (AB, 2 H, J = 16.4 Hz), 5.06 (t, 2 H, 
J = 13.6 Hz), 2.46 (s, 3 H), 2.34 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.3, 152.9, 150.1, 
140.8, 138.6, 136.6, 136.3, 128.9, 128.5, 128.3, 127.8, 127.7, 126.8, 126.1, 103.1, 65.2, 52.2, 
44.9, 20.6 16.0; HRMS (EI+) m/z calcd for C27H27N2O3 ([M+H]+) 427.5179, found 427.2011. 
Benzyl-1-benzyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-
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5-carboxylate (2.5). According to General Procedure A, benzylurea (0.250 g, 1.63 mmol), 4-
anisaldehyde (409 µL, 3.33 mmol), benzyl acetoacetate (557 µL, 3.26 mmol), and conc. HCl 
(0.100 mL, 1.17 mmol) were stirred at room temperature for 42 h and provided a crude residue 
that was recrystallized using t-butyl methyl ether to afford 2.5 (411 mg, 0.929 mmol, 57%) as a 
red-orange solid: MP 132-134 °C; IR (neat) 3346, 3065, 3026, 2938, 2832, 1700, 1605, 1385, 
1197, 1160, 1109, 1035, 757, 720, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.25 (m, 8 H), 
7.19-7.10 (CDCl3 overlap, m, 8 H), 6.79 (d, 2 H, J = 8.0 Hz), 5.44 (bs, 1 H), 5.41 (bs, 1 H), 5.19, 
4.93 (AB, 2 H, J = 16.4 Hz), 5.09, 5.05 (AB, 2 H, J = 12.6 Hz), 3.81 (s, 3 H), 2.47 (s, 3 H); 13C 
NMR (100 MHz, CDCl3), δ 165.8, 159.2, 153.6, 149.4, 137.9, 135.9, 135.4, 128.7, 128.4, 128.1, 
128.0, 127.7, 127.2, 126.5, 114.0, 104.5, 66.1, 55.3, 53.6, 46.0, 16.6; HRMS (EI+) m/z calcd for 
C27H27N2O4 ([M+H]+) 443.1900, found 443.1962. 
(Note: this compound is commercially available from Aurora Screening Library, 
however, characterization data has yet to be published in the literature) 
Benzyl-1-benzyl-6-methyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-
5-carboxylate (2.6). According to General Procedure A, benzylurea (0.250 g, 1.63 mmol), 2-
naphthaldehyde (0.520 g, 3.26 mmol), benzyl acetoacetate (557 µL, 3.26 mmol), and conc. HCl 
(0.100 mL, 1.17 mmol) were stirred at room temperature for 42 h and provided a crude residue 
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that was recrystallized using hexanes/ethyl acetate (1:1) to afford 2.6 (578 mg, 1.25 mmol, 77%) 
as a pale-orange solid: MP 165-167 °C; IR (neat) 3236, 3115, 3040, 1713, 1687, 1611, 1383, 
1206, 1156, 1105, 1042, 738, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.84-7.79 (m, 1 H), 7.74 
(d, 1 H, J = 8.4 Hz), 7.68-7.63 (m, 1 H), 7.58 (s, 1 H), 7.56-7.45 (m, 2 H), 7.34 (d, 1 H, J = 8.8 
Hz), 7.25-7.22 (m, 3 H), 7.22-7.14 (m, 4 H), 7.08 (d, 2 H, J  = 7.6 Hz), 5.67 (d, 1 H, J = 18.0 
Hz), 5.61 (s, 1 H), 5.26, 4.90 (AB, 2 H, J = 16.0 Hz), 5.06, 5.02 (AB, 2 H, J = 12.2 Hz), 2.51 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 165.7, 153.5, 149.9, 140.2, 137.8, 135.8, 133.2, 128.8, 
128.7, 128.4, 128.1, 128.0, 127.6, 127.3, 126.5, 126.2, 126.1, 125.3, 124.5, 104.1, 66.2, 54.4, 
46.0, 16.6; HRMS (EI+) m/z calcd for C30H27N2O3 ([M+H]+) 463.1900, found 463.2016. 
Benzyl-4-(4-chlorophenyl)-1-(4-methoxybenzyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.7). According to General Procedure A, 1-(4-
methoxybenzyl)urea (299 mg, 1.56 mmol), benzaldehyde (318 µL, 3.12 mmol), benzyl 
acetoacetate (533 µL, 3.12 mmol), and conc. HCl (0.100 mL, 1.17 mmol) were stirred at room 
temperature for 44 h and provided a crude residue that was recrystallized using hexanes/ethyl 
acetate (1:1) to afford 2.7 (600. mg, 1.36 mmol, 87%) as a light yellow solid: MP 138-140 °C; IR 
(neat) 3346, 3026, 2951, 1706, 1700, 1681, 1613, 1197, 1160, 1104, 1027, 701 cm-1, 1H NMR 
(400 MHz, CDCl3) δ 7.30-7.24 (m, 4 H), 7.20-7.16 (m, 2 H), 7.14-7.10 (m, 2 H), 7.10-7.05 (m, 2 
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H), 6.83-6.80 (m, 2 H), 5.48 (bs, 1 H), 5.43 (d, 1 H, J = 2.8 Hz), 5.14, 4.82 (AB, 2 H, J = 16.0 
Hz), 5.07, 5.04 (AB, 2 H, J = 12.4 Hz), 3.79 (s, 3 H), 2.48 (s, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 165.7, 158.7, 153.5, 149.8, 142.9, 135.8, 129.8, 128.7, 128.4, 128.0, 127.8, 126.4, 114.0, 104.2, 
66.0, 55.2, 54.1, 16.5; HRMS (EI+) m/z calcd for C27H27N2O4 ([M+H]+) 
443.1900, found 443.1963. 
Benzyl-4-(4-chlorophenyl)-1-(4-methoxybenzyl)-6-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.8). According to General Procedure A, 1-(4-
methoxybenzyl)urea (302 mg, 1.58 mmol), 4-chlorobenzaldehyde (444 mg, 3.13 mmol), benzyl 
acetoacetate (535 µL, 3.13 mmol), and conc. HCl (0.100 mL, 1.17 mmol) were stirred at room 
temperature for 44 h and provided a crude residue that was recrystallized using hexanes/ethyl 
acetate (1:1) to afford 2.8 (636 mg, 1.33 mmol, 85%) as a light yellow solid: MP 185-187 °C; IR 
(neat) 3341, 3026, 2945, 1706, 1681, 1613, 1517, 1385, 1247, 1197, 1160, 1104, 815, 733 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.31-7.27 (m, 3 H), 7.20-7.16 (m, 2 H), 7.15-7.11 (m, 2 H), 7.09-
7.03 (m, 4 H), 6.85-6.80 (m, 2 H), 5.68 (d, 1 H, J = 11.2 Hz), 5.39 (d, 1 H, J = 2.8 Hz), 5.14, 
4.78 (AB, 2 H, J = 16.0 Hz), 5.09, 5.01 (AB, 2 H, J = 12.2 Hz), 3.80 (s, 3 H), 2.49 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 165.5, 158.9, 153.5, 150.1, 141.6, 135.7, 133.6, 129.7, 128.8, 128.5, 
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128.2, 127.9, 114.1, 104.4, 66.2, 55.3, 53.5, 45.5, 16.6; HRMS (EI+) m/z calcd for C27H26N2O4Cl 
([M+H]+) 477.1500, found 477.1576. 
Benzyl-1-(4-methoxybenzyl)-6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.9). According to General Procedure A, 1-(4-
methoxybenzyl)urea (305 mg, 1.59 mmol), p-tolualdehyde (377 µL, 3.13 mmol), benzyl 
acetoacetate (535 µL, 3.13 mmol), and conc. HCl (0.100 mL, 1.17 mmol) were stirred at room 
temperature for 44 h and provided a crude residue that was recrystallized using hexanes/ethyl 
acetate (1:1) to afford 2.9 (573 mg, 1.56 mmol, 79%) as a pale orange solid: MP 155-157 °C; IR 
(neat) 3346, 3001, 2932, 1706, 1681, 1613, 1393, 1197, 1160, 1104, 733 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.50-7.46 (CDCl3 overlap, m, 7 H), 7.36-7.31 (m, 2 H), 7.30-7.27 (m, 4 H), 
7.05-7.00 (m, 2 H), 5.63 (bs, 1 H), 5.59 (d, 1 H, J = 2.8 Hz), 5.34, 5.03 (AB, 2 H, J = 16.2 Hz), 
5.26, 5.24 (AB, 2 H, J = 12.6 Hz), 4.00 (s, 3 H), 2.67 (s, 3 H), 2.53 (s, 3 H); 13C NMR (100 
MHz, CDCl3) δ 165.8, 158.8, 153.6, 149.6, 140.2, 137.6, 136.0, 130.0, 129.4, 128.4, 128.1, 
128.0, 127.9, 126.4, 114.1, 104.4, 66.1, 55.3, 54.0, 45.5, 21.1, 16.6; HRMS (EI+) m/z calcd for 
C28H29N2O4 ([M+H]+) 457.2000, found 457.2119. 
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Benzyl-3-acetyl-1-benzyl-6-methyl-2-oxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2.10).63 To a suspension of 2.1 (0.200 g, 0.469 mmol, 1.0 equiv) in THF (24.0 mL, 
0.02 M) in a flame-dried flask under an Ar atmosphere at -78 °C was added n-BuLi (325 µL, 
0.520 mmol, 1.1 equiv) drop-wise to afford a clear yellow solution. The reaction mixture was 
warmed to room temperature, stirred for 30 min, cooled to -78 °C, and quenched via the drop-
wise addition of distilled acetyl chloride (37.0 µL, 0.520 mmol, 1.1 equiv). The reaction mixture 
was stirred at -78 °C for 5 min and warmed to room temperature. After 20 min of stirring at 
room temperature the reaction mixture was washed using cold sat.’d NH4Cl (25 mL) and 
extracted using ethyl acetate (25 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and dried under high-vacuum to afford 2.10 (223 mg, 
0.476 mmol, >99%) as a yellow wax: 1H NMR (400 MHz, d6-DMSO) δ 7.40-7.28 (m, 5 H), 
7.19-7.09 (m, 5 H), 6.97 (d, 2 H, J = 7.6 Hz), 6.83 (d, 2 H, J = 7.2 Hz), 6.60 (s, 1 H), 5.24, 5.18 
(AB, 2 H, J = 12.4 Hz), 5.16, 4.76 (AB, 2 H, J = 16.2 Hz), 2.46 (s, 3 H), 2.41 (s, 3 H), 2.30 (s, 3 
H); 13C NMR (100 MHz, d6-DMSO) δ 171.1, 164.7, 152.0, 149.8, 137.1, 136.9, 136.0, 135.9, 
129.0, 128.4, 128.3, 128.0, 127.0, 126.3, 125.8, 108.7, 65.8, 49.8, 46.0, 25.3, 20.6, 15.9; HRMS 
(EI+) m/z calcd for C29H29N2O4 ([M+H]+) 469.2000, found 469.2120.  
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2,2,2',2'-Tetramethyl-[4,4'-bi(1,3-dioxolane)]-5,5'-dione (2.12).57 To a solution of L-
tartaric acid (5.00 g, 32.98 mmol, 1.0 equiv) in acetone (47.1 mL, 0.7 M) was added 2,2-
dimethoxypropane (41.2 mL, 330. mmol, 10 equiv) followed by the drop-wise addition of boron 
trifluoride ether complex (835 µL, 6.60 mmol, 0.2 equiv). The reaction mixture was heated at 50 
°C for 3 h and concentrated under reduced pressure to a volume of ~20 mL. Additional acetone 
(38 mL) and 2,2-dimethoxypropane (7.00 mL, 18.1 mmol, 0.6 equiv) was added and the reaction 
mixture was heated at 50 °C for 30 min. The reaction mixture was concentrated under reduce 
pressure to a volume of ~20 mL and additional acetone (38 mL) and 2,2-dimethoxypropane (7.00 
mL, 18.1 mmol, 0.6 equiv) was added. The reaction mixture was heated at 50 °C for 30 min, 
concentrated under reduced pressure, and diluted using t-butyl methyl ether (25 mL). The 
reaction mixture was washed with sat.’d NaHCO3 (25 mL) and resulting organic extract was 
diluted using heptane (25 mL). The reaction mixture was concentrated under reduced pressure to 
a volume of ~10 mL and diluted further using heptane (50 mL). The suspension was cooled at -
20 °C for 2 h, filtered, and rinsed with heptane to afford 2.12 (3.52 g, 15.2 mmol, 46%) as a 
white crystalline solid. The remaining filtrate was concentrated under reduced pressure, diluted 
with heptane (50 mL), and stored at -20 °C overnight to afford additional 2.12 (993 mg, 4.29 
mmol, 13 %, 59% overall) as a white crystalline solid: 1H NMR (400 MHz, CDCl3) δ 4.81 (s, 2 
H), 1.66 (s, 6 H), 1.59 (s, 6 H). 
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(Z)-2-(2,2-Dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid (2.13).57 To a solution of 
2.12 (1.84 g, 7.99 mmol, 1.0 equiv) in THF (15 mL, dry - still, 0.5 M) in a flame-dried flask 
under an Ar atmosphere at -40 °C was added sodium t-butoxide (1.03 g, 10.5 mmol, 1.3 equiv) 
as a THF (8.0 mL, dry - still, 1.3 M) solution drop-wise over ~5 min. The reaction mixture was 
stirred at -40 °C for 20 min, quenched via the drop-wise addition of HCl in dioxane (3.0 mL, 
12.0 mmol, 1.5 equiv), and warmed to room temperature. The reaction mixture was diluted using 
EtOAc (75 mL) and washed with 1 M HCl (25 mL). The the resulting organic extract was 
washed with water (25 mL), dried (Na2SO4), and concentrated under reduced pressure to afford a 
light brown crude residue. The resulting crude residue was triturated with t-butyl methyl ether to 
afford a white precipitate which was filtered and rinsed with additional t-butyl methyl ether to 
afford 2.13 (949 mg, 5.51 mmol, 69%) as a white powder: 1H NMR (300 MHz, d6-DMSO) δ 
12.62 (s, 1 H), 5.56 (s, 1 H), 1.70 (s, 6 H). 
 
 
 
 
(Z)-2-(2,2-Dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl chloride (2.14)57 To a 
solution of 2.13 (50.0 mg, 0.290 mmol, 1.0 equiv) in CH2Cl2 (1.0 mL, dry-still, 0.3 M) in a 
flame-dried vial under an Ar atmosphere was added distilled oxalyl chloride (27.0 µL, 0.315 
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mmol, 1.1 equiv) drop-wise followed by a trace amount of DMF (1 drop, dry). The reaction 
mixture was stirred at room temperature for 30 min and concentrated under reduced pressure to 
afford 2.14 (55.0 mg, 0.289 mmol, quant) as an off-white crystalline solid: 1H NMR (400 MHz, 
CDCl3) δ 6.17 (s, 1 H), 1.78 (s, 6 H). 
 
 
 
 
 
(Z)-Benzyl-1-benzyl-3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl)-6-
methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.15). To a solution of 
2.1 (50.0 mg, 0.121 mmol, 1.0 equiv) in CH2Cl2 (518 µL, 0.2 M) was added 2.13 (42.0 mg, 
0.244 mmol, 2.0 equiv), T3P (159 µL, 0.267 mmol, 2.2 equiv) as a 50% ethyl acetate solution, 
DMAP (6.0 mg, 0.048 mmol, 0.4 equiv), and Et3N (85.0 µL, 0.609 mmol, 5.0 equiv) 
sequentially. The reaction mixture was stirred at room temperature for 48 h, diluted using ethyl 
acetate (5 mL), washed with sat.’d NaHCO3 (5 mL), and extracted with ethyl acetate (5 mL, 3x). 
The combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure. 
The resulting crude residue was recrystallized using hexanes/chloroform to afford 2.15 (16.5 mg, 
0.0291 mmol, 24%) as a mild brown solid: MP 206-208 °C; IR (neat) 3033, 2983, 2925, 1788, 
1687, 1631, 1385, 1260, 1255, 1191, 1141, 1009, 751, 701 cm-1; 1H NMR (500 MHz, d6-
acetone) δ 7.36-7.24 (m, 9 H), 7.22-7.11 (m, 6 H), 6.87 (d, 2 H, J = 7.0 Hz), 6.78 (s, 1 H), 6.74 
(s, 1 H), 5.42, 4.76 (AB, 2 H, J = 16.5), 5.29, 5.21 (AB, 2 H, J = 12.5), 2.53 (s, 3 H), 1.76 (s, 3 
H), 1.74 (s, 3 H); 13C NMR (125 MHz, d6-acetone) δ 165.8, 164.2, 162.9, 153.4, 150.7, 148.0, 
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140.3, 138.0, 137.3, 129.4, 129.0, 128.9, 128.7, 128.0, 127.6, 127.4, 115.1, 110.6, 98.4, 67.0, 
51.8, 47.1, 26.6, 26.5, 16.5; HRMS (EI+) m/z calcd for C33H31N2O7 ([M+H]+) 567.2179, found 
567.2129. 
 
 
 
 
 
 
(Z)-Benzyl-1-benzyl-4-(4-chlorophenyl)-3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-
ylidene)acetyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.16). 
According to General Procedure B, 2.2 (51.0 mg, 0.114 mmol), 2.13 (39.4 mg, 0.229 mmol), 
T3P (147 µL, 0.247 mmol), DMAP (6.0 mg, 0.049 mmol), and Et3N (79.0 µL, 0.562 mmol) 
were heated at 100 °C for 1 h using microwave irradiation. The reaction mixture was diluted 
using ethyl acetate (2 mL), washed with sat.’d NaHCO3 (2 mL), and extracted using ethyl acetate 
(2 mL, 3x). The combined organic extracts were washed with water (15 mL), dried (Na2SO4), 
and concentrated under reduced pressure. The resulting crude residue was purified using 
chromatography on SiO2 (ISOC-Rf, 4 g column, step-wise gradient using hexanes/ethyl acetate) 
to afford a pale yellow solid. The solid was triturated with cold hexanes to afford 2.16 (27.2 mg, 
0.0453 mmol, 40%) as a white solid: MP 184-186 °C; IR (neat) 3039, 2970, 1795, 1687, 1631, 
1493, 1385, 1247, 1210, 1186, 1096, 1027, 1003, 757, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.32-7.27 (CDCl3 overlap, m, 1 H), 7.24-7.10 (m, 9 H), 7.07-7.04 (m, 2 H), 6.85 (s, 1 H), 6.84 
(bs, 2 H), 6.64 (s, 1 H), 5.38, 4.62 (AB, 2 H, J = 15.6 Hz), 5.23, 5.09 (AB, 2 H, J = 12.4 Hz), 
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2.53 (s, 3 H), 1.76 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 164.8, 163.9, 161.9, 152.2, 149.4, 
147.5, 137.2, 136.1, 135.5, 133.8, 128.7, 128.6, 128.3, 128.1, 127.8, 127.2, 114.4, 109.9, 98.1, 
66.6, 51.0, 46.7, 26.8, 16.4; HRMS (EI+) m/z calcd for C33H30N2O7Cl ([M+H]+) 601.1736, found 
601.1740. 
 
 
 
 
 
 
(Z)-Benzyl-1-benzyl-3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl)-6-
methyl-2-oxo-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(2.17). According to General Procedure B, 2.3 (0.150 g, 0.312 mmol), 2.13 (107 mg, 0.622 
mmol), T3P (409 µL, 0.687 mmol), DMAP (15.0 mg, 0.122 mmol), and Et3N (219 µL, 1.56 
mmol) were heated at 100 °C for 1 h using microwave irradiation. The reaction mixture was 
diluted using ethyl acetate (2 mL), washed with sat.’d NaHCO3 (2 mL), and extracted using ethyl 
acetate (2 mL, 3x). The combined organic extracts were washed with water (15 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The resulting crude residue was purified 
using chromatography on SiO2 (ISOC-Rf, 4 g column, step-wise gradient using hexanes/ethyl 
acetate) to afford (Z)-benzyl 1-benzyl-3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl)-
6-methyl-2-oxo-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(0.120 g, 0.190 mmol, 61%) as a off-white foam: IR (neat) 3025, 2945, 1801, 1687, 1637, 1379, 
1323, 1247, 1178, 1122, 1072, 751, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, 2 H, J = 
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8.0 Hz), 7.33-7.29 (m , 3 H), 7.27-7.18 (m, 5 H), 7.16-7.10 (m, 2 H), 6.88 (s, 1 H), 6.81 (d, 2 H, 
J = 7.2 Hz), 6.74 (s, 1 H), 5.41, 4.64 (AB, 2 H, J = 16.0 Hz), 5.27, 5.13 (AB, 2 H, J = 12.4 Hz), 
2.57 (s, 3 H), 1.77 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 164.7, 163.9, 161.9, 152.2, 149.7, 
148.7, 142.8, 135.9, 135.4, 130.1 (q, J = 32.0 Hz), 128.7, 128.6, 128.3, 128.1, 127.8, 127.0, 
125.4 (t, J = 3.6 Hz), 123.9 (q, J = 27.1 Hz), 114.4, 109.7, 97.9, 66.7, 51.1, 46.7, 30.9, 26.8, 16.4; 
HRMS (EI+) m/z calcd for C34H30F3N2O7 ([M+H]+) 635.2000, found 635.1987. 
 
 
 
 
Methyl-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(2.19).70 To a solution of 1-methyl urea (1.01 g, 13.2 mmol, 1.0 equiv) in THF (65.5 mL, 0.2 M, 
dry-solvent system) under an Ar atmosphere was added benzaldehyde (2.70 mL, 26.2 mmol, 2.0 
equiv) and methyl acetoacetate (2.90 mL, 26.6 mmol, 2.0 equiv). The reaction mixture was 
stirred for 5 min at room temperature and conc. HCl (785 µL, 9.14 mmol, 0.7 equiv) was added 
drop-wise to the reaction to afford a clear solution. The reaction mixture was stirred at room 
temperature for 3 days. The reaction mixture was concentrated under reduced pressure to afford 
a crude yellow solid. The resulting crude residue was purified via recrystallization using EtOAc 
to afford methyl 1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.49 
g, 9.57 mmol, 72%) as an off-white powder: 1H NMR (400 MHz, CDCl3) δ 7.38-7.24 (CDCl3 
overlap, m, 5 H), 5.63 (bs, 1 H), 5.41 (s, 1 H), 3.68 (s, 3 H), 3.26 (s, 3 H), 2.54 (s, 3 H). 
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Tert-butyl (3-bromopropyl)carbamate (2.20).71 To a mixture of 1-bromopropyl amine 
hydrobromide (1.25 g, 5.60 mmol, 1.0 equiv) in CH2Cl2 (20 mL, 0.28 M, dry-solvent system) at 
0 °C was added triethylamine (0.780 mL, 5.55 mmol, 1.0 equiv) to afford a clear solution. A 
solution of Boc-anhydride (1.26 g, 5.72 mmol, 1.0 equiv) in CH2Cl2 (50 mL, 0.11 M, dry-solvent 
system) was added drop-wise to the reaction mixture over 10 min. The reaction mixture was 
stirred at 0 °C for 2-3 min, warmed to room temperature, and stirred for 2 h. The reaction 
mixture was diluted using ethyl acetate (100 mL), washed with 5% citric acid (50 mL), and 
extracted using ethyl acetate (50 mL, 3x). The combined organic extracts were washed with 
brine (100 mL), dried (Na2SO4), concentrated under reduced pressure, and dried under high 
vacuum to afford Boc-aminopropyl bromide (1.25 g, 5.25 mmol, 94%) as a very light yellow oil: 
1H NMR (300 MHz, CDCl3) δ 4.65 (s, 1 H), 3.44 (t, 2 H, J = 6.3 Hz), 3.33 (q, 2 H, J = 6.5 Hz), 
2.09-2.00 (m, 2 H), 1.44 (s, 9 H). 
1-Benzyl-3-(3-((tert-butoxycarbonyl)amino)propyl)-6-methyl-2-oxo-4-phenyl- 
1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.21). To a solution of 2.1 (201 mg, 0.487 mmol, 
1.0 equiv) in DMF (5.0 mL, 0.1 M, dry) in a flame-dried flask under an Ar atmosphere at 0 °C 
was added NaH (30.0 mg, 0.750 mmol, 1.5 equiv) as a 60% dispersion in mineral oil. The 
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reaction mixture was stirred until bubbling stopped and 2.20 (148 mg, 0.622 mmol, 1.3 equiv) as 
a DMF (448 µL, 1.3 M, dry) solution was added drop-wise to the reaction mixture. The reaction 
mixture was stirred for 3.5 h at 0 °C, warmed to room temperature overnight, quenched with 
sat.'d NH4Cl (10 mL) and water (10 mL), and extracted with EtOAc (20 mL, 3x). The combined 
organic extracts were washed with brine (50 mL), dried (Na2SO4), and concentrated under 
reduced pressure to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3 hexanes/acetone) to afford 2.21 (134 mg, 0.235 mmol, 48%) as a 
white foam: IR (neat) 3353, 3033, 2969, 2932, 1700, 1668, 1625, 1493, 1448, 1392, 1254, 1204, 
1165, 1135, 1077, 1034, 733, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.30 (m, 5 H), 7.30- 
7.13 (CDCl3 overlap, m, 6 H), 7.13-7.08 (m, 4 H), 5.39 (s, 1 H), 5.21, 5.11 (AB, 2 H, J = 12.3 
Hz), 5.23, 4.97 (AB, 2 H, J = 16.5), 3.91-3.88 (m, 1 H), 3.33-3.18 (m, 1 H), 3.11-2.94 (m, 2 H), 
2.46 (s, 3 H), 1.77-1.64 (m, 2 H), 1.46 (s, 9 H); 13C NMR (100 MHz, CDCl3), δ 165.7, 156.0, 
153.9, 149.5, 141.4, 137.9, 135.9, 128.7, 128.5, 128.4, 128.2, 127.9, 127.2, 126.8, 126.5, 104.2, 
66.3, 58.9, 46.8, 28.4, 27.9, 16.7; HRMS (EI+) m/z calcd for C34H39N3O5Na ([M+Na]+) 
592.2782, found 592.2767. 
Methyl-3-(3-((tert-butoxycarbonyl)amino)propyl)-1,6-dimethyl-2-oxo-4-phenyl- 
1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.22). To a solution of 2.19 (201 mg, 0.772 
mmol, 1.0 equiv) in DMF (7.7 mL, 0.1 M, dry) in a flame-dried flask at 0 °C under an Ar 
atmosphere was added sodium hydride (46.5 mg, 1.16 mmol, 1.5 equiv) as a 60% dispersion in 
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mineral oil. The reaction mixture was stirred at 0 °C until bubbling stopped and 2.20 (0.220 g, 
0.924 mmol, 1.2 equiv) was added drop-wise as a DMF (0.710 mL, 1.3 M, dry) solution. The 
reaction mixture was stirred at 0 °C for 4 h, warmed to room temperature overnight, quenched 
using sat.'d NH4Cl (5 mL) and water (5 mL), and extracted using EtOAc (15 mL, 3x). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried 
using high vacuum to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3, hexanes/acetone, isocratic) to afford methyl 2.22 (25.3 mg, 0.0606 
mmol, 8%) as a white foam. An additional fraction of product was collected (52.4 mg, 0.109 
mmol, 87% pure, 14%) with the impurity being remaining pyrimidinone starting material. The 
pure material was fully characterized and then combined with the impure fractions for the 
following de-protection step (70.9 mg, 0.155 mmol, 91% pure, 20% combined): IR (neat) 3353, 
2969, 2924, 2855, 1694, 1663, 1625, 1512, 1461, 1366, 1254, 1165, 1053, 725, 701 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.33-7.18 (CDCl3 overlap, m, 5 H), 5.29 (s, 1 H), 5.12 (s, 1 H), 3.81-
3.70 (m, 1 H), 3.70 (s, 3 H), 3.24 (s, 3 H), 3.24-3.11 (m, 1 H), 3.02-2.89 (m, 2 H), 2.46 (s, 3 H), 
1.70-1.60 (m, 2 H), 1.42 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 166.3, 156.0, 154.3, 149.5, 
141.6, 128.7, 127.8, 126.4, 103.8, 78.9, 58.6, 51.3, 44.2, 37.4, 31.2, 28.4, 28.0, 16.6; HRMS 
(EI+) m/z calcd for C22H31N3O5Na ([M+Na]+) 440.2156, found 440.2147. 
3-(3-Benzyl-5-((benzyloxy)carbonyl)-4-methyl-2-oxo-6-phenyl-2,3-
dihydropyrimidin-1(6H)-yl)propan-1-aminium chloride (2.23). A solution of 2.21 (92.2 mg, 
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0.161 mmol, 1.0 equiv) in 4 M HCl in dioxane (0.810 mL, 3.24 mmol, 20.0 equiv) was stirred at 
room temperature for 27.5 h, concentrated under reduced pressure, rinsed with ether, and dried 
using high vacuum to afford 2.23 (81.6 mg, 0.161 mmol, quant) as an off-white foam: IR (neat) 
3403, 3088, 2945, 2882, 1650, 1631, 1456, 1385, 1286, 1204, 1135, 1077, 1027, 990, 725, 695 
cm-1; 1H NMR (300 MHz, d6-DMSO) δ 7.38 (s, 3 H), 7.30-7.11 (CDCl3 overlap, m, 15 H), 5.37 
(s, 1 H), 5.14, 5.04 (AB, 2 H, J = 12.6 Hz), 5.09, 4.93 (AB, 2 H, J = 16.5 Hz), 3.69-3.57 (m, 2 
H), 3.36-3.28 (m, 1 H), 3.08-2.95 (m, 1 H), 2.80-2.66 (m, 2 H), 2.36 (s, 3 H), 1.88-1.68 (m, 2 H); 
13C NMR (100 MHz, d6-DMSO) δ 165.0, 152.9, 149.5, 141.4, 138.3, 136.1, 128.5, 128.3, 127.9, 
127.0, 126.6, 126.4, 103.4, 65.5, 58.4, 46.0, 44.1, 36.6, 25.8, 16.2; HRMS (EI+) m/z calcd for 
C29H32N3O3 ([M+H]+) 470.2438, found 470.2421. 
 
 
 
 
3-(5-(Methoxycarbonyl)-3,4-dimethyl-2-oxo-6-phenyl-3,6-dihydropyrimidin-1(2H)-
yl)propan-1-aminium chloride (2.24). To a solution of 2.22 (68.8 mg, 0.165 mmol, 1.0 equiv) 
in THF (825 uL, 0.2 M) was added 4M HCl (825 uL, 3.30 mmol, 20 equiv). The reaction 
mixture was stirred at room temperature overnight, concentrated under reduced pressure, rinsed 
with ether, and dried using high vacuum to afford 2.24 (58.6 mg, 0.151 mmol, 91% pure, 91%) 
as a yellow-green foam: IR (neat) 3422, 2932, 2855, 1650, 1467, 1273, 1204, 1053, 764, 725 cm-
1; 1H NMR (300 MHz, d6-DMSO) δ 8.06 (bs, 1 H), 7.89 (bs, 2 H), 7.40-7.17 (m, 5 H), 5.30 (s, 1 
H), 3.62 (s, 3 H), 3.47-3.33 (m, 1 H), 3.16 (s, 3 H), 3.02-2.83 (m, 1 H), 2.78-2.67 (m, 2 H), 2.45 
(s, 3 H), 1.83-1.68 (m, 2 H); 13C NMR (100 MHz, d6-DMSO) δ 166.3, 153.7, 150.7, 142.2, 
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129.3, 128.4, 126.9, 103.3, 58.7, 51.8, 44.4, 37.1, 26.4, 16.7; HRMS (EI+) m/z calcd for 
C17H24N3O3 ([M+H]+) 318.1812, found 318.1804. 
 
 
 
 
(Z)-Benzyl-1-benzyl-3-(3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-
ylidene)acetamido)propyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (2.25). To a solution of 2.23 (176 mg, 0.264 mmol, 1.0 equiv) in CH2Cl2 (1.9 mL, 
0.1 M, dry-solvent system) under an Ar atmosphere was added 2.13 (55.2 mg, 0.321 mmol, 1.2 
equiv), T3P (189 µL, 0.317 mmol, 1.2 equiv) as a 50% EtOAc solution, and N,N-
diisopropylethylamine (0.230 mL, 1.32 mmol, 5.0 equiv). The reaction mixture was stirred 
overnight at room temperature, diluted using EtOAc (3 mL), washed with sat.'d NaHCO3 (2 mL), 
and extracted using EtOAc (2 mL, 3x). The combined organic extracts were washed with brine 
(5 mL), dried (Na2SO4), concentrated under reduced pressure, and dried under high vacuum to 
afford a crude residue. The resulting crude residue was purified using chromatography on SiO2 
(ISCO-Rf, hexanes/EtOAc, step-wise gradient) to afford 2.25 (118 mg, 0.189 mmol, 72%) as a 
white foam: IR (neat) 3316, 3070, 2995, 2945, 1795, 1668, 1625, 1385, 1260, 1210, 1135, 1008, 
733, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.46-7.35 (m, 1 H), 7.35-7.30 (m, 6 H), 7.30-7.15 
(CDCl3 overlap, m, 6 H), 7.15-7.10 (m, 4 H), 5.81 (s, 1 H), 5.32 (s, 1H), 5.18-5.98 (m, 4 H), 
3.78-3.69 (m, 1H), 3.53-3.42 (m, 1 H), 3.18-3.05 (m, 2 H), 2.43 (s, 3H), 1.69-1.59 (m, 5H), 1.54 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.6, 163.2, 161.9, 154.1, 149.2, 142.7, 141.6, 137.9, 
135.9, 135.8, 128.8, 128.6, 128.5, 128.4, 128.2, 128.0, 127.3, 126.9, 126.2, 113.7, 104.2, 101.7, 
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66.4, 59.2, 47.0, 44.1, 35.7, 27.2, 26.5, 16.7; HRMS (EI+) m/z calcd for C36H38N3O7 ([M+H]+) 
624.2704, found 624.2695. 
 
 
 
 
Methyl-(Z)-3-(3-(2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetamido)propyl)-
1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2.26). To a 
solution of 2.24 (64.1 mg, 0.138 mmol, 1.0 equiv) in CH2Cl2 (986 µL, 0.14 M, dry-solvent 
system) was added 2.13 (29.5 mg, 0.171 mmol, 1.2 equiv), T3P (99.0 µL, 0.166 mmol, 1.2 
equiv) as a 50% solution in EtOAc, and N,N-diisopropylethylamine (0.120 mL, 0.689 mmol, 5.0 
equiv). The reaction mixture was stirred overnight under an Ar atmosphere, diluted using EtOAc 
(5 mL), washed with sat.'d NaHCO3 (5 mL), and extracted using EtOAc (5 mL, 3x). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried 
using high vacuum to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.26 (45.7 mg, 0.0969 mmol, 
70%) as a white foam: IR (neat) 3295, 3001, 2945, 1795, 1663, 1631, 1536, 1467, 1385, 1254, 
1204, 1008, 902, 725 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.26 (m, 2 H), 7.26-7.23 (m, 1 
H), 7.23-7.18 (m, 2 H), 5.83 (s, 1 H), 5.27 (s, 1 H), 3.79-3.67 (m, 1 H), 3.69 (s, 3 H), 3.52-3.39 
(m, 1 H), 3.24 (s, 3 H), 3.12-2.98 (m, 2 H), 2.46 (s, 3 H), 1.74 (s, 6 H), 1.72-1.62 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 166.2, 163.1, 162.0, 154.3, 149.3, 142.7, 141.7, 128.6, 127.9, 126.4, 
113.7, 103.8, 101.5, 58.8, 51.3, 43.9, 35.7, 31.1, 27.2, 26.7, 16.5; HRMS (EI+) m/z calcd for 
C22H31N3O5Na ([M+Na]+) 472.2078, found 472.2067. 
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(Z)-4-((3-(3-Benzyl-5-((benzyloxy)carbonyl)-4-methyl-2-oxo-6-phenyl-2,3- 
dihydropyrimidin-1(6H)-yl)propyl)amino)-2-hydroxy-4-oxobut-2-enoic acid (2.27). To a 
solution of 2.25 (60.5 mg, 0.070 mmol, 1.0 equiv) in THF (1.8 mL) and water (603 µL, 0.04 M 
overall) was added 1 M NaOH (106 µL, 0.106 mmol, 1.1 equiv). The reaction mixture was 
stirred at room temperature for 3.5 h, quenched using 1 M HCl (0.200 mL) and water (2 mL) and 
extracted using EtOAc (5 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure (no heat), and dried using high vaccum to afford 2.27 (57.5 
mg, 0.0985 mmol, quant,) as a white foam (unknown impurity remained): IR (neat) 3334, 3025, 
2932, 1631, 1448, 1385, 1254, 1204, 1135, 1072, 1034, 725, 701 cm-1; 1H NMR (CDCl3, 300 
MHz) δ 7.35-7.30 (m, 7 H), 7.30-7.15 (CDCl3 overlap, m, 3 H), 7.15-7.05 (m , 5 H), 6.28 (s, 1 
H), 5.37 (s, 1 H), 5.23-5.06 (m, 3 H), 4.92 (d, 1 H, J = 16.5 Hz), 3.90-3.76 (m, 1 H), 3.48-3.39 
(m, 2 H), 3.18-3.03 (m, 2 H), 2.44 (s, 3 H), 1.78-1.63 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 
186.4, 170.6, 165.4, 164.4, 156.6, 154.6, 148.8, 140.6, 137.1, 135.6, 128.9, 128.8, 128.6, 128.4, 
128.3, 127.5, 126.7, 126.5, 105.2, 99.3, 66.6, 58.9, 47.2, 44.7, 35.9, 30.3, 16.7; HRMS (EI+) m/z 
calcd for C33H34N3O7 ([M+H]+) 584.2391, found 584.2382. 
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(Z)-2-Hydroxy-4-((3-(5-(methoxycarbonyl)-3,4-dimethyl-2-oxo-6-phenyl-3,6-
dihydropyrimidin-1(2H)-yl)propyl)amino)-4-oxobut-2-enoic acid (2.28). To a solution of 
2.26 (45.7 mg, 0.0969 mmol, 1.0 equiv) in THF/water (3:1, 1.8 mL THF, 0.600 mL water) at 
room temperature was added 1 M NaOH (116 uL, 0.116 mmol, 1.2 equiv). The reaction mixture 
was stirred at room temperature for 2 h quenched with 1 M HCl (1 mL) and extracted using 
EtOAc (5 mL, 3x). The combined organic extracts were dried (Na2SO4), concentrated under 
reduced pressure, rinsed with ether, and dried using high vacuum to afford 2.28 (38.4 mg, 0.0890 
mmol) as an impure (unknown impurity remained) off-white foam: 1H NMR (500 MHz, CDCl3) 
δ 7.35-7.25 (CDCl3 overlap, m, 5 H), 6.43 (s, 1 H), 5.33 (s, 1 H), 3.78-3.70 (m, 1 H), 3.71 (s, 3 
H), 3.44-3.36 (m, 1 H), 3.28 (s, 3 H), 3.15-3.05 (m, 2 H), 2.47 (s, 3 H), 1.76-1.65 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 170.7, 165.9, 164.7, 156.7, 155.1, 148.6, 141.0, 128.9, 128.3, 126.3, 
105.0, 99.5, 58.8, 51.3, 44.8, 35.6, 31.7, 26.7, 16.5; HRMS (EI+) m/z calcd for C21H28N3O7 
([M+H]+) 432.1765, found 432.1745. 
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Benzyl-1-benzyl-3-(2-ethoxy-2-oxoethyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.29). To a solution of 2.1 (202 mg, 0.490 mmol, 1.0 
equiv) in DMF (5.0 mL, 0.1 M, dry) in a flame-dried flask under an Ar atmosphere at 0 °C was 
added sodium hydride (33.0 mg, 0.825 mmol, 1.7 equiv) as a 60% dispersion in mineral oil. The 
reaction mixture was stirred at 0 °C until bubbling stopped and ethyl bromoacetate (60.0 µL, 
0.532 mmol, 1.1 equiv) was added drop-wise as a DMF (0.410 mL, 1.3 M, dry) solution. The 
reaction mixture was stirred at 0 °C for 3.5 h, quenched using sat.'d NH4Cl (10 mL) and water 
(10 mL) and extracted with EtOAc (20 mL, 3x). The combined organic extracts were washed 
with brine (20 mL), dried (Na2SO4), concentrated under reduced pressure, and dried under high 
vacuum to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.29 (195 mg, 0.391 mmol, 
80%) as an off-white solid: MP 75-77 °C; IR (neat) 3075, 2982, 2919, 1750, 1668, 1612, 1456, 
1385, 1191, 1072, 1027, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.38-7.23 (CDCl3 overlap, m, 5 
H), 7.23-7.18 (m, 6 H), 7.18-7.09 (m, 4 H), 5.40 (s, 1 H), 5.20, 4.96 (AB, 2 H, J = 16.8 Hz), 
5.10, 5.02 (AB, 2 H, J = 12.3), 4.52 (d, 1 H, J = 17.4 Hz), 4.24-4.07 (m, 2 H), 3.56 (d, 1H, J = 
17.4 Hz), 2.47 (s, 3), 1.22 (t, 3 H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 168.9, 165.5, 
153.2, 149.0, 140.5, 137.9, 135.9, 128.7, 128.6, 128.4, 128.2, 128.1, 127.3, 127.2, 126.6, 104.1, 
66.2, 61.2, 60.3, 48.2, 46.9, 16.7, 14.1; HRMS (EI+) m/z calcd for C30H31N2O5 ([M+H]+) 
499.2227, found 499.2216. 
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Benzyl-1-benzyl-3-(3-methoxy-3-oxopropyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.30). To a solution of 2.1 (101 mg, 0.245 mmol, 1.0 
equiv) in DMF (2.7 mL, dry, 0.09 M) at 0 °C in a flame-dried flask under an Ar atmosphere was 
added sodium hydride (18.3 mg, 0.458 mmol, 1.9 equiv) as a 60% dispersion in mineral oil. The 
reaction mixture was stirred at 0 °C until bubbling stopped and methyl 3-bromopropionate (32.0 
µL, 0.294 mmol. 1.2 equiv) was added drop-wise as a DMF (224 µL, dry, 1.3 M) solution. The 
reaction mixture was stirred at 0 °C for ~2.5 h and warmed to room temperature overnight. The 
reaction mixture was quenched using sat.'d NH4Cl (2 mL) and water (2 mL), and extracted using 
EtOAc (10 mL, 3x). The combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4), concentrated under reduced pressure, and dried using high vacuum to afford a crude 
residue. The resulting crude residue was purified using chromatography on SiO2 (7:3, 
hexanes/acetone, isocratic) to afford 2.30 (78.7 mg, 0.158 mmol, 64%) as an opaque oil residue: 
IR (neat) 3033, 2951, 1737, 1668, 1618, 1385, 1210 1135, 1040, 701 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.40-7.30 (m, 5 H), 7.30-7.21 (CDCl3 overlap, m, 5 H), 7.21-7.10 (m, 5 H), 5.52 (s, 1 
H), 5.23, 4.94 (AB, 2 H, J = 16.4 Hz), 5.18, 5.13 (AB, 2 H, J = 12.4 Hz), 3.97-3.88 (m, 1 H), 
3.63 (s, 3 H), 3.41-3.32 (m, 1 H), 2.80-2.71 (m, 1 H), 2.54-2.46 (m, 1 H), 2.46 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 172.1, 165.5, 153.3, 149.3, 141.3, 137.8, 135.9, 128.6, 128.5, 128.4, 128.3, 
128.2, 128.0, 127.8, 127.1, 126.8, 126.5, 104.3, 66.1, 59.8, 51.6, 46.6, 43.9, 32.9, 16.6; HRMS 
(EI+) m/z calcd for C30H31N2O5 ([M+H]+) 499.2277, found 499.2220. 
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Benzyl-1-benzyl-3-(4-ethoxy-4-oxobutyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.31). To a solution of 2.1 (102 mg, 0.247 mmol, 1.0 
equiv) in DMF (2.7 mL, dry, 0.09 M) at 0 °C in a flame-dried flask under an Ar atmosphere was 
added sodium hydride (16.8 mg, 0.420 mmol, 1.7 equiv) as a 60% dispersion in mineral oil. The 
reaction mixture was stirred at 0 °C until bubbling stopped and ethyl 4-bromobutyrate (42.0 µL, 
0.279 mmol, 1.1 equiv) was added drop-wise as a DMF (224 µL, dry, 1.3 M) solution. The 
reaction mixture was stirred at 0 °C for ~2.5 h and warmed to room temperature overnight. The 
reaction mixture was quenched using sat.d' NH4Cl (2 mL) and water (2 mL) and extracted using 
EtOAc (10 mL, 3x). The combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4), concentrated under reduced pressure, and dried using high vacuum to afford a crude 
residue. The resulting crude residue was purified using chromatography on SiO2 (7:3, 
hexanes/acetone, isocratic) to afford 2.31 (12.0 mg, 0.0228 mmol, 22%) as an opaque oil gum: 
IR (neat) 3025, 2932, 1726, 1668, 1618, 1456, 1385, 1204, 1135, 1066, 706, 701 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.35-7.26 (m, 6 H), 7.26-7.15 (CDCl3 overlap, m, 4 H), 7.15-7.06 (m, 5 H), 
5.39 (s, 1 H), 5.21, 4.90 (AB, 2 H, J = 16.5 Hz), 5.18, 5.09 (AB, 2 H, J = 12.5 Hz), 4.10 (q, 2 H, 
J = 7.0 Hz), 3.90-3.82 (m, 1 H), 2.95-2.88 (m, 1 H), 2.43 (s, 3 H), 2.38-2.26 (m, 2 H), 2.00-1.90 
(m, 1 H), 1.90-1.81 (m, 1 H), 1.23 (t, 3 H, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 173.0, 
165.7, 153.6, 149.7, 141.2, 138.0, 135.9, 128.6, 128.5, 128.2, 128.1, 127.8, 127.1, 126.8, 126.6, 
104.2, 66.2, 60.4, 58.6, 46.8, 46.3, 31.5, 22.9, 16.7, 14.2; HRMS (EI+) m/z calcd for C32H35N2O5 
([M+H]+) 527.2540, found 527.2534. 
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Methyl-3-(2-ethoxy-2-oxoethyl)-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.32). To a solution of 2.19 (0.150 g, 0.576 mmol, 1.0 
equiv) in DMF (6.4 mL, dry, 0.09 M) at 0 °C in a flame-dried flask under an Ar atmosphere was 
added sodium hydride (32.9 mg, 0.823 mmol, 1.4 equiv) as a 60% dispersion in mineral oil. The 
reaction mixture was stirred at 0 °C until bubbling stopped and methyl 3-bromopropionate (78.0 
uL, 0.692 mmol. 1.2 equiv) was added drop-wise as a DMF (532 uL, dry, 1.3 M) solution. The 
reaction mixture was stirred at 0 °C for ~3.5 h, warmed to room temperature overnight, quenched 
using sat.'d NH4Cl (10 mL) and water (10 mL), and extracted using EtOAc (20 mL, 3x). The 
combined organic extracts were washed with brine (30 mL), dried (Na2SO4), concentrated under 
reduced pressure, and dried using high vacuum to afford a crude residue (0.240 g, 145% mass 
recovery). The resulting crude residue was purified using chromatography on SiO2 (7:3, 
hexanes/acetone, isocratic) to afford 2.32 (166 mg, 0.479 mmol, 83%) as an opaque gum: IR 
(neat) 2999, 2943, 1750, 1670, 1625, 1452, 1279, 1191, 1066, 701 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.34-7.15 (CDCl3 overlap, m, 5 H), 5.35 (s, 1 H), 4.53, 3.50 (AB, 2 H, J = 17.4 Hz), 
4.28-4.05 (m, 2 H), 3.64 (s, 3 H), 3.26 (s, 3 H), 2.48 (s, 3 H), 1.22 (t, 3 H, J = 7.2 Hz); 13C NMR 
(100 MHz, CDCl3) δ 169.1, 166.2, 153.5, 149.1, 140.8, 128.7, 128.1, 126.9, 103.9, 61.2, 60.0, 
51.3, 47.8, 31.2, 16.7, 14.1; HRMS (EI+) m/z calcd for C18H23N2O5 ([M+H]+) 347.1601, found 
347.1596. 
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Ethyl-3-(3-methoxy-3-oxopropyl)-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.33). To a solution of 2.19 (0.150 g, 0.576 mmol, 1.0 
equiv) in DMF (6.4 mL, dry, 0.09 M) at 0 °C in a flame-dried flask under an Ar atmosphere was 
added sodium hydride (41.5 mg, 1.04 mmol, 1.8 equiv) as a 60% dispersion in mineral oil. The 
reaction mixture was stirred at 0 °C until bubbling stopped and methyl 3-bromopropionate (75.0 
uL, 0.687 mmol, 1.2 equiv) was added dropwise as a DMF (532 uL, dry, 1.3 M) solution. The 
reaction mixture was stirred at 0 °C for 2 h, warmed to room temperature overnight, quenched 
using sat.'d NH4Cl (5 mL) and water (5 mL), and extracted using EtOAc (10 mL,3x). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure, and dried 
using high vacuum to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.33 (121 mg, 0.349 mmol, 
61%) as a clear oil: IR (neat) 3033, 2951, 1737, 1663, 1631, 1435, 1279, 1204, 1154, 1059, 701 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.34-7.15 (CDCl3 overlap, m, 5 H), 5.42 (s, 1 H), 3.88-3.78 
(m, 1 H), 3.69 (s, 3 H), 3.63 (s, 3 H), 3.37-3.24 (m, 1 H), 3.24 (s, 3 H), 2.75-2.63 (m, 1 H), 2.51-
2.41 (m, 1 H), 2.45 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 172.0, 166.1, 153.5, 149.2, 141.5, 
128.5, 127.7, 126.3, 103.9, 59.6, 51.5, 51.1, 43.6, 32.8, 30.8, 16.4; HRMS (EI+) m/z calcd for 
C18H23N2O5 ([M+H]+) 347.1601, found 347.1584. 
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2-(3-Benzyl-5-((benzyloxy)carbonyl)-4-methyl-2-oxo-6-phenyl-2,3-
dihydropyrimidin-1(6H)-yl)acetic acid (2.34). To a solution of 2.29 (57.1 mg, 0.115 mmol, 1.0 
equiv) in 3:1 THF/water (2.2 mL THF, 725 µL water, 0.04 M) was added 1 M NaOH (138 µL, 
0.138 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for 4 h, quenched 
using 1 M HCl (1 mL) and extracted using EtOAc (5 mL, 3x). The combined organic extracts 
were dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum to 
afford an off-white foam. The resulting foam was rinsed with ether concentrated under reduced 
pressure and dried using high vacuum to afford 2.34 (45.1 mg, 0.0959 mmol, 84%) as a white 
foam: IR (neat) 3033, 2924, 1700, 1668, 1630, 1456, 1392, 1210, 1135, 1085, 746, 701 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.35-7.19 (CDCl3 overlap, m, 11 H), 7.17-7.11 (m, 4 H), 5.40 (s, 1 
H), 5.18, 4.98 (AB, 2 H, J = 16.4 Hz), 5.10, 5.02 (AB, 2 H, J = 12.0 Hz), 4.39, 3.79 (AB, 2 H, J 
= 17.6 Hz), 2.48 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 172.1, 165.4, 153.7, 148.7, 140.1, 
137.5, 135.7, 128.8, 128.5, 128.4, 128.3, 128.2, 127.4, 127.3, 126.6, 104.5, 66.3, 60.8, 48.6, 47.0, 
16.7; HRMS (EI+) m/z calcd for C28H27N2O5 ([M+H]+) 471.1914, found 471.1899. 
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3-(3-Benzyl-5-((benzyloxy)carbonyl)-4-methyl-2-oxo-6-phenyl-2,3-
dihydropyrimidin-1(6H)-yl)propanoic acid (2.35).  To a solution of 2.30 (14.9 mg, 0.0300 
mmol, 1.0 equiv) in THF/water (3:1, 564 µL THF, 188 µL water) was added 1 M NaOH (36.0 
µL, 0.036 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for 2.5 h, 
quenched using 1 M HCl (0.5 mL), and extracted using EtOAc (3 mL, 3x). The combined 
organic extracts were washed with brine (5 mL), dried (Na2SO4), concentrated under reduced 
pressure, and dried using high vacuum to afford 2.35 (13.4 mg, 0.0277 mmol, 93%) as a white 
foam: IR (neat) 3202, 3033, 2924, 1737, 1694, 1631, 1456, 1316, 1210, 1178, 1141, 1085, 738, 
701 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34-7.27 (m, 2 H), 7.26-7.10 (CDCl3 overlap, m, 8 H), 
7.10-7.00 (m, 5 H), 5.44 (s, 1 H), 5.15, 4.86 (AB, 2 H, J = 16.4 Hz), 5.10, 5.02 (AB, 2 H, J = 
12.4 Hz), 3.82-3.75 (m, 1 H), 3.48-3.28 (m, 1 H), 2.73-2.66 (m, 1 H), 2.48-2.40 (m, 1 H), 2.38 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 176.3, 165.6, 153.6, 149.3, 141.2, 137.8, 135.9, 128.7, 
128.5, 128.3, 128.1, 128.0, 127.2, 126.8, 126.6, 104.6, 66.3, 60.2, 46.7, 43.8, 32.9, 16.7; HRMS 
(EI+) m/z calcd for C29H29N2O5 ([M+H]+) 485.2071, found 485.2061. 
 
 
 
 
 
 
 79 
 
 
 
4-(3-Benzyl-5-((benzyloxy)carbonyl)-4-methyl-2-oxo-6-phenyl-2,3-
dihydropyrimidin-1(6H)-yl)butanoic acid (2.36). To a solution of 2.31 (29.0 mg, 0.0551 
mmol, 1.0 equiv) in THF/water (3:1, 1.0 mL THF, 345 µL water) was added 1 M NaOH (66.0 
µL, 0.0661 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for 3.5 h, 
additional 1 M NaOH (20.0 µL, 0.02 mmol, 0.4 equiv) was added, and the reaction mixture was 
stirred overnight at room temperature. The reaction mixture was quenched using 1 M HCl (1 
mL), and extracted using EtOAc (5 mL, 3x). The combined organic extracts were washed with 
brine (5 mL), dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum 
to afford 2.36 (20.0 mg, 0.0401 mmol, 73%) as a white foam: IR (neat) 3170, 3070, 3025, 2919, 
2850, 1700, 1668, 1625, 1456, 1392, 1204, 1135, 1077, 733, 695 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.34-7.10 (CDCl3 overlap, m, 11 H), 7.10-7.00 (m, 4 H), 5.33 (s, 1 H), 5.14, 4.84 (AB, 
2 H, J = 16.2 Hz), 5.11, 5.02 (AB, 2 H, J = 12.3 Hz), 3.86-3.77 (m, 1 H), 2.96-2.87 (m, 1 H), 
2.36 (s, 3 H), 2.36-2.27 (m, 2 H), 1.89-1.75 (m, 2 H; 13C NMR (100 MHz, CDCl3) δ 177.8, 
165.6, 153.9, 149.6, 141.1, 137.9, 135.9, 128.7, 128.6, 128.5, 128.3, 128.1, 127.9, 127.2, 127.0, 
126.8, 126.6, 104.4, 66.3, 58.7, 46.8, 46.2, 31.2, 22.8, 16.7; HRMS (EI+) m/z calcd for 
C30H31N2O5 ([M+H]+) 499.2227, found 499.2216. 
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2-(5-(Methoxycarbonyl)-3,4-dimethyl-2-oxo-6-phenyl-3,6-dihydropyrimidin-1(2H)-
yl)acetic acid (2.37). To a solution of 2.32 (72.0 mg, 0.208 mmol, 1.0 equiv) in THF/water (3:1, 
3.9 mL THF, 1.3 mL water) was added 1 M NaOH (0.250 mL, 0.250 mmol, 1.2 equiv). The 
reaction mixture was stirred at room temperature for 2.5 h, quenched using 1 M HCl (3 mL), and 
extracted using EtOAc (10 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, rinsed with ether, and dried using high vacuum to afford 
2.37 (66.9 mg, 0.210 mmol, 101%) as a white foam: IR (neat) 3051, 2956, 2837, 1700, 1631, 
1480, 1305, 1215, 1072, 751, 733 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (m, 3 H), 7.24-
7.18 (m, 2 H), 5.34 (s, 1 H), 4.49, 3.63 (AB, 2 H, J = 17.4 Hz), 3.66 (s, 3 H), 3.29 (s, 3 H), 2.50 
(s, 3 H); 13C NMR (100 MHz, CDCl3) δ 173.1, 166.2, 153.9, 148.8, 140.5, 128.9, 128.4, 126.9, 
104.2, 60.4, 51.4, 48.2, 31.3, 16.8; HRMS (EI+) m/z calcd for C16H19N2O5 ([M+H]+) 319.1288, 
found 319.1283. 
 
 
 
 
3-(5-(Methoxycarbonyl)-3,4-dimethyl-2-oxo-6-phenyl-3,6-dihydropyrimidin-1(2H)-
yl)propanoic acid (2.38). To a solution of 2.33 (81.1 mg, 0.234 mmol, 1.0 equiv) in THF/water 
(3:1 THF/water, 4.4 mL THF, 1.5 mL water, 0.04 M) was added 1 M NaOH (281 uL, 0.281 
mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for ~3 h, quenched using 
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1 M HCl (4 mL), and extracted using EtOAc (10 mL, 3x). The combined organic extracts were 
dried (Na2SO4), concentrated under reduced pressure, rinsed with ether, and dried using high 
vacuum to afford 2.38 (80.6 mg, 0.243 mmol, 104%) as a white foam: IR (neat) 3316, 3070, 
2951, 1694, 1625, 1461, 1310, 1191, 1172, 1122, 1027, 839, 733 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 9.85 (bs, 1 H), 7.35-7.15 (CDCl3 overlap, m, 5 H), 5.44 (s, 1 H), 3.86-3.76 (m, 1 H), 
3.68 (s, 3 H), 3.38-3.25 (m, 1 H), 3.23 (s, 3 H), 2.78-2.65 (m, 1 H), 2.54-2.45 (m, 1 H), 2.45 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 176.6, 166.2, 153.9, 149.2, 141.4, 128.7, 127.9, 126.3, 104.2, 
59.8, 51.3, 43.6, 32.9, 30.9, 16.5; HRMS (EI+) m/z calcd for C17H21N2O5 ([M+H]+) 333.1445, 
found 333.1439. 
 
 
 
 
Benzyl-1-benzyl-3-(cyanomethyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.39). To a solution of 2.1 (0.100 g, 0.242 mmol, 1.0 
equiv) in MECN (1.0 mL, 0.24 M, dry) and DMF (0.5 mL, dry) in a flame-dried flask under an 
Ar atmosphere at 0 °C was added NaH (15.0 mg, 0.375 mmol, 1.5 equiv) as a 60% dispersion in 
mineral oil. The reaction mixture was stirred until bubbling stopped and chloroacetonitrile (19.0 
µL, 0.297 mmol, 1.2 equiv) was added as a DMF (0.200 mL, 1.3 M, dry) solution. The reaction 
mixture was stirred at 0 C for ~2 h, warmed to room temperature for 2 h, quenched using sat.'d 
NH4Cl (5 mL) and water (5 mL), and extracted using EtOAc (10 mL, 3x). The combined organic 
extracts were dried (Na2SO4), concentrated under reduced pressure, and dried under high vacuum 
to afford a crude residue. The resulting crude residue was purified using chromatography on 
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SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.39 (52.7 mg, 0.117 mmol, 48%) as a white 
foam: IR (neat) 3057, 2945, 2246, 1668, 1618, 1448, 1385, 1204, 1135, 1072, 1027, 733, 701 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.41-7.35 (m, 1 H), 7.35-7.26 (CDCl3 overlap, m, 6 H), 
7.26-7.21 (m, 4 H), 7.20-7.15 (m, 4 H), 5.53 (s, 1 H), 5.21, 4.90 (AB, 2 H, J = 16.5 Hz), 5.14, 
5.06 (AB, 2 H, J = 12.3 Hz), 4.76 (d, 1 H, J = 17.4 Hz), 3.74 (d, 1 H, J = 17.4), 2.53 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 164.9, 152.5, 148.6, 138.7, 137.2, 135.5, 128.9, 128.8, 128.7, 128.4, 
128.3, 128.2, 128.1, 127.5, 127.2, 126.6, 114.8, 104.4, 66.4, 59.7, 47.1, 34.2, 16.6; HRMS (EI+) 
m/z calcd for C28H26N3O3 ([M+H]+) 452.1969, found 452.1961. 
 
 
 
 
Benzyl-1-benzyl-3-(2-cyanoethyl)-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.40). To a solution of 2.1 (0.150 g, 0.364 mmol, 1.0 
equiv) in DMF (1.5 mL, 0.24 M, dry) in a flame-dried flask under an Ar atmosphere at 0 °C was 
added NaH (21.8 mg, 0.545 mmol, 1.5 equiv) as a 60% dispersion in mineral oil. The reaction 
mixture was stirred until bubbling stopped and chloroacetonitrile (37.0 uL, 0.436 mmol, 1.2 
equiv) was added as a DMF (335 uL, 1.3 M, dry). The reaction mixture was stirred at 0 °C for 
~3.25 h, warmed to room temperature overnight, quenched using sat.'d NH4Cl (5 mL) and water 
(5 mL), and extracted using EtOAc (10 mL, 3x). The combined organic extracts were washed 
with brine (15 mL), dried (Na2SO4), concentrated under reduced pressure, and dried using high 
vacuum to afford a crude residue. The resulting crude residue was purified using 
chromatography on SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.40 (127 mg, 0.273 mmol, 
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75%) as a white foam: IR (neat) 3038, 2956, 2253, 2253, 1663, 1625, 1456, 1385, 1204, 1135, 
1072, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.42-7.25 (CDCl3 overlap, m, 10 H), 7.25-7.12 
(m, 5 H), 5.49 (s, 1 H), 5.23, 4.98 (AB, 2 H, J  = 16.5 Hz), 5.18, 5.10 (AB, 2 H, J = 12.3 Hz), 
3.91-3.78 (m, 1 H), 3.42-3.28 (m, 1 H), 2.85-2.70 (m, 1 H), 2.50 (s, 3 H), 2.43-2.32 (m, 1 H); 13C 
NMR (125 MHz, CDCl3) δ 165.2, 153.1, 148.9, 140.7, 137.5, 135.6, 128.7, 128.6, 128.3, 128.2, 
128.0, 127.2, 126.7, 126.4, 117.6, 104.4, 66.2, 60.5, 46.6, 44.0, 16.5; HRMS (EI+) m/z calcd for 
C29H28N3O3 ([M+H]+) 466.2125, found 466.2119. 
 
 
 
 
Methyl 3-(cyanomethyl)-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-
5-carboxylate (2.41). To a solution of 2.19 (151 mg, 0.580 mmol, 1.0 equiv) in DMF (2.4 mL, 
0.24 M, dry) in a flame-dried flask under an Ar atmosphere at 0 °C was added NaH (36.0 mg, 
0.900 mmol, 1.6 equiv) as a 60% dispersion in mineral oil. The reaction mixture was stirred until 
bubbling stopped and chloroacetonitrile (44.2 uL, 0.691 mmol, 1.2 equiv) was added as a DMF 
(532 uL, 1.3 M, dry) solution. The reaction mixture was stirred at 0 °C for ~2 h, warmed to room 
temperature overnight, quenched using sat.'d NH4Cl (5 mL) and water (5 mL), and extracted 
using EtOAc (10 mL, 3x). The combined organic extracts were dried (Na2SO4), concentrated 
under reduced pressure, and dried using high vacuum to afford a crude residue (236 mg, 130% 
mass recovery). The resulting crude residue was purified using chromatography on SiO2 (7:3, 
hexanes/acetone, isocratic) to afford 2.41 (92.7 mg, 0.310 mmol, 53%) as a white foam: IR 
(neat) 2956, 2913, 1705, 1676, 1637, 1456, 1286, 1210, 1066, 751, 706 cm-1; 1H NMR (400 
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MHz, CDCl3) δ 7.38-7.30 (m, 3H), 7.25-7.22 (m, 2 H), 5.45 (s, 1 H), 4.73 (d, 1 H, J = 17.6 Hz), 
3.70 (d, 1 H, J = 19.2 Hz), 3.67 (s, 3 H), 3.31 (s, 3 H), 2.52 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 165.7, 152.7, 148.6, 139.1, 129.1, 128.8, 126.9, 115.0, 104.3, 59.5, 51.5, 34.2, 31.3, 
16.7; HRMS (EI+) m/z calcd for C17H20N3O3 ([M+H]+) 314.1499, found 314.1493. 
 
 
 
 
Methyl-3-(2-cyanoethyl)-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-
5-carboxylate (2.42). To a solution of 2.19 (0.151 g, 0.580 mmol, 1.0 equiv) in DMF (2.4 mL, 
0.24 M, dry) in a flame-dried flask under an Ar atmosphere at 0 °C was added NaH (39.0 mg, 
0.975 mmol, 1.7 equiv) as a 60% dispersion in mineral oil. The reaction mixture was stirred until 
bubbling stopped and chloroacetonitrile (58.5 uL, 0.692 mmol, 1.2 equiv) was added as a DMF 
(532 uL, 1.3 M, dry). The reaction mixture was stirred at 0 °C for ~2 h, warmed to room 
temperature overnight, quenched using sat.'d NH4Cl (5 mL) and water (5 mL), and extracted 
using EtOAc (10 mL, 3x). The combined organic extracts were dried (Na2SO4), concentrated 
under reduced pressure, and dried using high vacuum to afford a crude residue (236 mg, 130% 
mass recovery). The resulting crude residue was purified using chromatography on SiO2 (7:3, 
hexanes/acetone, isocratic) to afford 2.42 (83.9 mg, 0.268 mmol, 48%) as a clear gum: IR (neat) 
3033, 2956, 2253, 1700, 1663, 1631, 1435, 1210, 1059, 1021, 725 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.35-7.27 (m, 3 H), 7.22-7.18 (m, 2 H), 5.40 (s, 1 H), 3.80 (ddd, 1 H, J = 13.6, 8.0, 4.8 
Hz), 3.69 (s, 3 H), 3.29 (ddd, 1 H, J = 14.8, 7.2, 4.8 Hz), 3.27 (s, 3 H), 2.73 (ddd, 1 H, J = 16.8, 
8.0, 8.0 Hz), 2.36 (ddd, 1 H, J = 16.8, 4.8, 4.8 Hz); 13C NMR (100 MHz, CDCl3) δ 166.0, 153.5, 
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149.0, 141.2, 129.0, 128.3, 126.5, 117.8, 104.3, 60.5, 51.4, 44.1, 31.0, 16.7, 16.6; HRMS (EI+) 
m/z calcd for C16H18N3O3 ([M+H]+) 300.1343, found 300.1337. 
 
 
 
 
Benzyl-3-((1H-tetrazol-5-yl)methyl)-1-benzyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.43). To a solution of 2.39 (54.9 mg, 0.122 mmol, 1.0 
equiv) in THF (422 µL, 0.3 M, solvent system) in a microwave vial was added trimethylsilyl 
azide (66.0 µL, 0.484 mmol, 4.0 equiv) and tetrabutyl ammonium fluoride (122 µL, 0.122 mmol, 
1.0 equiv) as a 1.0 M THF solution. The reaction mixture was heated at 90 °C overnight in a 
sealed tube to afford a clear, light yellow solution. The reaction mixture was quenched using 1 M 
HCl (0.5 mL) and water (0.5 mL) and extracted using EtOAc (3 mL, 3x). The combined organic 
extracts were washed with brine (5 mL), dried (Na2SO4), concentrated under reduced pressure, 
and dried using high vacuum to afford a crude oil residue (92 mg, 153% mass recovery). The 
resulting crude residue was re-extracted using 1 M HCl (2 mL) and EtOAc (5 mL). The resulting 
organic extract was washed with water (3 mL, 2x), washed with brine (3 mL), dried (Na2SO4), 
concentrated under reduced pressure, and dried using high-vacuum to afford 2.43 (35.4 mg, 
0.0716 mmol, 59%) as a white foam: IR (neat) 3033, 2937, 2869, 1663, 1631, 1448, 1385, 1204, 
1135, 1053, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 13.70 (bs, 1 H), 7.37-7.23 (CDCl3 overlap, 
m, 7 H), 7.23-7.10 (m, 8 H), 5.55 (s, 1 H), 5.12, 5.02 (AB, 2 H, J = 17.1 Hz), 5.11, 5.03 (AB, 2 
H, J = 12.3 Hz), 4.74, 4.52 (AB, 2 H, J = 15.3 Hz), 2.46 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
164.8, 154.4, 152.2, 148.0, 139.6, 136.9, 135.4, 128.8, 128.6, 128.5, 128.3, 128.2, 127.5, 127.1, 
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126.1, 105.2, 66.5, 61.1, 47.1, 40.5, 16.5; HRMS (EI+) m/z calcd for C28H27N6O3 ([M+H]+) 
495.2139, found 495.2132. 
 
 
 
 
Benzyl-3-(2-(1H-tetrazol-5-yl)ethyl)-1-benzyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.44). To a solution of 2.40 (89.0 mg, 0.191 mmol, 1.0 
equiv) in THF (637 uL, 0.3 M) in a microwave vial was added trimethylsilyl azide (104 uL, 
0.751 mmol, 3.9 equiv) and tetrabutyl ammonium fluoride (191 uL, 0.191 mmol, 1.0 equiv) as a 
1.0 M THF solution. The reaction mixture was heated at 90 °C overnight in a sealed tube, 
quenched using 1 M HCl (5 mL) and extracted using EtOAc (10 mL, 3x ). The combined organic 
extracts were washed with water (10 mL, 2x) and brine (10 mL), dried (Na2SO4), concentrated 
under reduced pressure, and dried using high vacuum to afford a crude oil residue. The resulting 
crude residue was purified using chromatography on SiO2 (ISCO-Rf, CH2Cl2/MeOH, 0-10% 
MeOH gradient) to afford 2.44 (18.6 mg, 0.0366 mmol, 19%) as a white foam and recovered 
starting material (28.9 mg, 0.0621 mmol, 32% recovery): IR (neat) 3144, 3033, 2924, 1668, 
1631, 1456, 1385, 1204, 1135, 725, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.38-7.27 (m, 5 H), 
7.25-7.10 (m, 6 H), 7.10-7.02 (m, 4 H), 5.40 (s, 1 H), 5.16, 5.06 (AB, 2 H, J = 12.3 Hz), 5.12, 
4.98 (AB, 2 H, J = 16.2 Hz), 4.02-3.91 (m, 1 H), 3.69-3.58 (m, 1 H), 3.23-3.10 (m, 1 H), 3.09-
2.98 (m, 1 H), 2.41 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.1, 155.0, 154.0, 148.2, 140.5, 
137.0, 135.5, 128.9, 128.6, 128.5, 128.4, 127.5, 126.6, 126.2, 105.2, 66.6, 60.0, 47.2, 44.6, 23.2, 
16.6; HRMS (EI+) m/z calcd for C29H29N6O3 ([M+H]+) 509.2296, found 509.2291. 
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Methyl-3-((1H-tetrazol-5-yl)methyl)-1,6-dimethyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.45). To a solution of 2.41 (83.0 mg, 0.277 mmol, 1.0 
equiv) in THF (0.890 mL, 0.3 M, dry-solvent system) in a microwave vial was added 
trimethylsilyl azide (154 uL, 1.07 mmol, 4.0 equiv) and tetrabutyl ammonium fluoride (277 uL, 
0.267 mmol, 1.0 equiv) as a 1.0 M THF solution. The reaction mixture was heated at 90 °C 
overnight in a sealed tube, quenched using 1 M HCl (5 mL), and extracted using EtOAc (5 mL, 
3x). The combined organic extract was washed with water (10 mL), dried (Na2SO4), 
concentrated under reduced pressure, and dried using high vacuum to afford a crude residue 
(77.3 mg, 82% mass recovery). The resulting crude residue was purified using chromatography 
on SiO2 (ISCO-Rf, CH2Cl2/MeOH, 0-10% MeOH gradient) to afford 2.45 (45.9 mg, 0.134 
mmol, 48%) was a white foam: IR (neat) 3133, 3033, 2951, 2876, 1625, 1448, 1286, 1210, 1059, 
725 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27-7.23 (CDCl3 overlap, m, 3 H), 7.19-7.15 (m, 2 H), 
5.47 (s, 1 H), 4.70 (s, 2 H), 3.66 (s, 3 H), 3.34 (s, 3 H), 2.51 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 165.5, 154.9, 148.1, 139.9, 129.0, 128.7, 126.7, 105.1, 61.4, 51.5, 41.2, 31.2, 16.5; 
HRMS (EI+) m/z calcd for C16H19N6O3 ([M+H]+) 343.1496, found 343.1496. 
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2-(5-(Methoxycarbonyl)-6-methyl-2-oxo-4-phenyl-3,4-dihydropyrimidin-1(2H)-
yl)acetic acid (2.46). According to General Procedure A, carbamoylglycine (0.500 g, 4.23 
mmol, 1.0 equiv), benzaldehyde (872 uL, 8.47 mmol, 2.0 equiv), methyl acetoacetate (922 uL, 
8.47 mmol, 2.0 equiv), and HCl (254 uL, 2.96 mmol, 0.7 equiv) were stirred at room temperature 
for ~40 h and filtered to afford 2.46 (402 mg, 1.32 mmol, 31%) as a yellow solid: MP 175-177 
°C; IR (neat) 3284, 3046, 2937, 1700, 1663, 1618, 1435, 1316, 1204, 1103, 770, 701 cm-1; 1H 
NMR (300 MHz, d6-DMSO) δ 12.87 (bs, 1 H), 8.06 (d, 1 H, J = 3.0 Hz), 7.37-7.22 (m, 5 H), 
5.18 (d, 1 H, J  = 3.3 Hz), 4.47, 4.33 (AB, 2 H, J = 18.3 Hz), 3.56 (s, 3 H), 2.40 (s, 3 H); 13C 
NMR (100 MHz, d6-DMSO) δ 171.5, 166.6, 152.9, 149.9, 144.5, 128.9, 127.9, 126.9, 103.1, 
53.4, 51.7, 44.5, 27.3, 16.2; HRMS (EI+) m/z calcd for C15H17N2O5 ([M+H]+) 305.1132, found 
305.1124. 
 
 
 
 
 
3-(5-(Methoxycarbonyl)-6-methyl-2-oxo-4-phenyl-3,4-dihydropyrimidin-1(2H)-
yl)propanoic acid (2.47). According to General Procedure A, 3-ureidopropanoic acid (0.250 g, 
1.89 mmol, 1.0 equiv), benzaldehyde (0.390 mL, 3.79 mmol, 2.0 equiv), methyl acetoacetate 
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(412 uL, 3.78 mmol, 2.0 equiv), and conc. HCl (114 uL, 1.33 mmol, 0.7 equiv) were stirred at 
room temperature for 3.5 days and concentrated under reduced pressure. The resulting crude 
residue was purified using chromatography on SiO2 (ISCO-Rf, CH2Cl2/MeOH, 0-10% MeOH 
gradient) to afford 2.47 (160 mg, 0.503 mmol, 27%) as pale yellow foam: IR (neat) 3258, 3051, 
2945, 1681, 1650, 1430, 1385, 1191, 1103, 1046, 764, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.34-7.15 (CDCl3 overlap, m, 5 H), 6.51 (bs, 1 H), 5.36 (d, 1 H, J = 3.0 Hz), 4.11-3.90 (m, 2 H), 
3.65 (s, 3 H), 2.81-2.68 (m, 1 H), 2.62-2.50 (m, 1 H), 2.54 (s, 3 H); 13C NMR (100 MHz, CDCl3) 
δ 175.3, 166.4, 154.2, 148.3, 142.7, 128.8, 127.9, 126.1, 105.1, 53.7, 51.5, 38.6, 33.9, 16.1; 
HRMS (EI+) m/z calcd for C16H19N2O5 ([M+H]+) 319.1288, found 319.1284. 
 
 
 
 
 
 
4-(5-(Methoxycarbonyl)-6-methyl-2-oxo-4-phenyl-3,4-dihydropyrimidin-1(2H)-
yl)butanoic acid (2.48). According to General Procedure A, 4-ureidobutanoic acid (0.500 g, 
3.42 mmol, 1.0 equiv), benzaldehyde (704 uL, 6.84 mmol, 2.0 equiv), methyl acetoacetate (745 
uL, 6.84 mmol, 2.0 equiv), and conc. HCl (206 uL, 2.40 mmol, 0.7 equiv) were stirred at room 
temperature for ~36 h and filtered to afford 2.48 (606 mg, 1.82 mmol, 53%) as a white solid: MP 
224-225 °C; IR (neat) 3284, 3221, 3064, 2951, 2505, 1700, 1644, 1474, 1417, 1236, 1191, 1115, 
971, 751, 706 cm-1; 1H NMR (300 MHz, d6-DMSO) δ 12.07 (s, 1 H), 7.96 (d, 1 H, J = 3.6 Hz), 
7.35-7.18 (m, 5 H), 3.91-3.78 (m, 1 H), 3.57 (s, 3 H), 3.57-3.45 (m, 1 H), 2.13 (t, 2 H, J = 7.2 
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Hz), 2.09 (s, 3 H), 1.79-1.52 (m, 2 H); 13C NMR (100 MHz, d6-DMSO) δ 207.0, 174.4, 166.6, 
153.2, 150.3, 144.3, 129.0, 127.9, 126.5, 103.4, 52.7, 51.7, 41.5, 31.2, 25.1, 16.1; HRMS (EI+) 
m/z calcd for C17H21N2O5 ([M+H]+) 333.1445, found 333.1428. 
 
 
 
2-(4-Methoxybenzyl)isothiouronium chloride (2.49). To a mixture of thiourea (1.50 g, 
19.7 mmol, 1.0 equiv) in THF (9.9 mL, 2.0 M, dry-solvent system) at 0 °C was added 4-
methoxybenzyl chloride (2.73 mL, 19.7 mmol, 1.0 equiv) over ~2 min. The reaction mixture was 
allowed to warm to room temperature, stirred for 2 h, and then heated at 65 °C for 5 h. The 
resulting white solid was filtered and gently washed with ether to afford 2.49 (4.16 g, 17.9 mmol, 
91%) as a white powder: 1H NMR (300 MHz, d6-DMSO) δ 9.05 (bs, 4 H), 7.34 (d, 2 H, J = 8.4 
Hz), 6.93 (d, 2 H, J = 8.4 Hz), 4.42 (s, 2 H), 3.75 (s, 3 H). 
 
 
 
 
Methyl 2-benzylidene-3-oxobutanoate (2.50). To a solution of benzaldehyde (1.92 mL, 
18.5 mmol, 1.0 equiv) and methyl acetoacetate (2.01 mL, 18.5 mmol, 1.0 equiv) in 2-propanol 
(18.7 mL, 1.0 M) was added piperidine (74.0 uL, 0.749 mmol, 0.04 equiv) and acetic acid (43.0 
uL, 0.751 mmol, 0.04 equiv). The reaction mixture was stirred at room temperature for 44 h, 
concentrated under reduced pressure, and purified using chromatography on SiO2 (ISCO-Rf, 
hexanes/ethyl acetate) to afford 2.50 (2.95 g, 14.4 mmol, 78%, 1.8:1 mixture of the Z:E isomers) 
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as a yellow oil: 1H NMR (300 MHz, CDCl3) δ Z – major isomer  7.58 (s, 1 H), 7.48-7.35 (m, 5 
H), 3.84 (s, 3 H), 2.43 (s, 3 H), E – minor isomer 7.70 (s, 1 H), 7.45-7.33 (m, 5 H), 3.84 (s, 3 H), 
2.35 (s, 3 H). 
 
 
 
 
Methyl-2-((4-methoxybenzyl)thio)-6-methyl-4-phenyl-1,4-dihydropyrimidine-5-
carboxylate (2.51).68 To a solution of 2.50 (0.500 g, 2.45 mmol, 1.0 equiv) and 2.49 (0.569 g, 
2.45 mmol, 1.0 equiv) in DMF (6.1 mL dry, 0.4 M) was added sodium acetate (204 mg, 2.49 
mmol, 1.0 equiv). The reaction mixture was heated at 75 °C for 5 h, cooled to room temperature, 
quenched with water (20 mL), and extracted using EtOAc (20 mL, 3x). The combined organic 
extracts were dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum 
to afford a crude residue. The resulting crude residue was purified using chromatography on 
SiO2 (ISCO-Rf, hexanes/EtOAc) to afford 2.51 (0.620 g, 1.62 mmol, 66%, mixture of tautomers) 
as a light yellow foam: 1H NMR (300 MHz, CDCl3) δ 7.33-7.20 (m, 5 H), 6.89 (d, 2 H, J = 8.1 
Hz), 6.74 (d, 2 H, J = 8.1 Hz), 5.64 (bs, 1 H), 5.39 (d, 0.2 H, J = 2.7 Hz), 4.33, 4.09 (AB, 2 H, J 
= 13.5 Hz), 3.77 (s, 3 H), 3.63 (s, 3 H), 2.33 (s, 3 H). 
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Methyl-1-(2-ethoxy-2-oxoethyl)-2-((4-methoxybenzyl)thio)-6-methyl-4-phenyl-1,4-
dihydropyrimidine-5-carboxylate (2.52). To a solution of 2.51 (148 mg, 0.387 mmol, 1.0 
equiv) in DMF (1.3 mL, dry, 0.3 M) under an Ar atmosphere at 0 °C was added NaH (30.0 mg, 
0.750 mmol, 1.9 equiv) as a 60% dispersion in mineral oil. The reaction mixture was stirred at 0 
°C until bubbling stopped and ethyl bromoacetate (53.0 uL, 0.470 mmol, 1.2 equiv) was added 
dropwise as a DMF (361 uL, dry, 1.3 M) solution. The reaction mixture was warmed to room 
temperature, stirred overnight, quenched using sat.'d NH4Cl (3 mL) and water (3 mL), and 
extracted using EtOAc (5 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and dried using high vacuum to afford a crude residue (210 
mg, 116% mass recovery). The resulting crude residue was purified using chromatography on 
SiO2 (7:3, hexanes/acetone, isocratic) to afford 2.52 (138 mg, 0.295 mmol, 76%, single isomer) 
as a yellow oil: IR (neat) 2937, 2837, 1737, 1687, 1599, 1499, 1417, 1241, 1185, 1085, 1027, 
701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.33-7.21 (CDCl3 overlap, m, 8 H), 6.84 (d, 2 H, J = 8.4 
Hz), 5.28 (s, 1 H), 4.42, 4.28 (AB, 2 H, J = 13.2 Hz), 4.12, 3.90 (AB, 2 H, J = 18.0 Hz), 4.13-
3.95 (m, 2 H), 3.76 (s, 3 H), 3.59 (s, 3 H), 1.15 (t, 3 H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) 
δ 167.0, 161.2, 158.8, 153.9, 141.8, 130.2, 128.8, 128.5, 128.1, 127.3, 113.8, 104.6, 62.4, 61.5, 
55.1, 50.8, 50.7, 35.7, 30.8, 23.0, 13.9; HRMS (EI+) m/z calcd for C25H29N2O5S ([M+H]+) 
469.1792, found 469.1781. 
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Methyl-1-(3-methoxy-3-oxopropyl)-2-((4-methoxybenzyl)thio)-6-methyl-4-phenyl-
1,4-dihydropyrimidine-5-carboxylate (2.53). To a solution of 2.51 (0.150 g, 0.392 mmol, 1.0 
equiv) in DMF (1.3 mL, dry, 0.3 M) under an Ar atomsphere at 0 °C was added NaH (30.3 mg, 
0.758 mmol, 1.9 equiv) as a 60% dispersion in mineral oil. The reaction mixture was stirred at 0 
°C until bubbling stopped and methyl 3-bromopropionate (51.0 uL, 0.467 mmol, 1.2 equiv) was 
added dropwise as a DMF (361 uL, dry, 1.3 M) solution. The reaction mixture was warmed to 
room temperature, stirred overnight, quenched using sat.'d NH4Cl (3 mL) and water (3 mL), and 
extracted using EtOAc (5 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and dried using high vacuum to afford a crude residue. The 
resulting crude residue was purified using chromatography on SiO2 (7:3, hexanes/acetone, 
isocratic) to afford 2.53 (118 mg, 0.252 mmol, 64%) as a yellow oil (partially separable 4.4:1 
mixture of N1- and N3-isomers): IR (neat) 3308, 3038, 2956, 1694, 1612, 1512, 1435, 1241, 
1171, 1096, 1034, 839, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.20 (CDCl3 overlap, m, 7 
H), 6.85 (d, 2 H, J = 8.7 Hz), 5.34 (s, 1 H), 4.46, 4.31 (AB, 2 H, J = 13.5), 3.80 (s, 3 H), 3.68-
3.58 (m, 2 H), 3.65 (s, 3 H), 3.62 (s, 3 H), 2.71-2.56 (m, 1 H), 2.51-2.39 (m, 1 H), 2.38 (s, 3 H);  
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Methyl-1-(2-ethoxy-2-oxoethyl)-6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.54).68 To a solution of 2.52 (0.122 g, 0.260 mmol, 1.0 
equiv) in CH2Cl2 (3.06 mL, dry-solvent system, 0.085 M) was added trifluoroacetic acid (100 
uL, 1.31 mmol, 5.0 equiv) and ethanethiol (47.0 uL, 0.645 mmol, 2.5 equiv). The reaction 
mixture was stirred overnight at room temperature, concentrated under reduced pressure, and 
dissolved in EtOAc (10 mL). The solution was extracted using sat.'d NaHCO3 (10 mL), extracted 
using EtOAc (10 mL, 3x), dried (Na2SO4), concentrated under reduced pressure, and dried using 
high vacuum to afford a crude residue. The resulting crude residue was triturated using ether to 
afford 2.52 (60.0 mg, 0.172 mmol, 66%) as a pale yellow solid: MP 145-146 °C; IR (neat) 3215, 
3157, 3083, 2995, 1745, 1676, 1549, 1474, 1254, 1185, 1115, 1027, 701 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.75 (bs, 1 H), 7.40-7.20 (CDCl3 overlap, m, 5 H), 5.46 (s, 1 H), 5.26 (d, 1 H J = 
17.4 Hz), 4.30-4.13 (m, 2 H), 3.81 (d, 1 H, J = 17.4 Hz), 3.67 (s, 3 H), 2.34 (s, 3 H), 1.27 (t, 3 H, 
J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 176.1, 167.6, 165.5, 142.1, 140.2, 129.0, 128.6, 
127.2, 102.9, 62.2, 61.6, 52.8, 51.4, 18.4, 14.1; HRMS (EI+) m/z calcd for C17H21N2O4S 
([M+H]+) 349.1217, found 349.1211. 
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Methyl-1-(3-methoxy-3-oxopropyl)-6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (2.55).68 To a solution of 2.53 (56.9 mg, 0.121 mmol, 1.0 
equiv) in CH2Cl2 (1.4 mL, dry-solvent system, 0.085 M) was added trifluoroacetic acid (47.0 uL, 
0.614 mmol, 5.0 equiv) and ethanethiol (22.0 uL, 0.302 mmol, 2.5 equiv). The reaction mixture 
was stirred overnight at room temperature, concentrated under reduced pressure, and dissolved in 
EtOAc (5 mL). The solution was extracted using sat.'d NaHCO3 (5 mL), extracted using EtOAc 
(5 mL, 3x), dried (Na2SO4), concentrated under reduced pressure, and dried using high vacuum 
to afford a crude residue. The resulting crude residue was triturated using ether to afford 2.55 
(30.0 mg, 0.0861 mmol, 71%) as a pale yellow foam: IR (neat) 3321, 3020, 2945, 1732, 1663, 
1525, 1435, 1241, 1197, 1165, 1109, 757, 701 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.90 (s, 1 H), 
7.38-7.22 (CDCl3 overlap, m, 5 H), 5.59 (s, 1 H), 4.37-4.26 (m, 1 H), 3.70 (s, 3 H), 3.62 (s, 3 H), 
3.01-2.98 (m, 1 H), 2.65-2.55 (m, 1 H), 2.30 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 175.2, 
171.8, 165.6, 142.5, 140.9, 129.8, 128.9, 128.4, 126.9, 114.0, 113.8, 102.8, 62.1, 51.8, 51.4, 48.5, 
31.8, 30.9; HRMS (EI+) m/z calcd for C17H21N2O4S ([M+H]+) 349.1217, found 349.1211. 
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2-(5-(Methoxycarbonyl)-6-methyl-4-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)acetic acid (2.56). To a solution of 2.54 (40.9 mg, 0.117 mmol, 1.0 equiv) in THF/water (3:1, 
2.19 mL THF, 731 uL THF, 0.04 M) was added 1 M NaOH (141 uL, 0.141 mmol, 1.2 equiv). 
The reaction mixture was stirred at room temperature for 2 h, quenched using 1 M HCl (2 mL), 
and extracted using EtOAc (5 mL, 3x). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and dried using high vacuum to afford 2.56 (38.6 mg, 
0.120 mmol, 103%) as a white foam: IR (neat) 3441, 3215, 2969, 1676, 1536, 1456, 1385, 1210, 
1103, 1046, 701 cm-1; 1H NMR (300 MHz, d4-MeOH) δ 7.39-7.26 (m, 5 H), 5.48 (s, 1 H), 5.22 
(d, 1 H, J = 17.4 Hz), 3.81 (d, 1 H, J = 17.4 Hz), 3.63 (s, 3 H), 2.32 (s, 3 H); 13C NMR (100 
MHz, d4-MeOH) δ 178.0, 171.4, 167.5, 145.2, 142.5, 130.0, 129.6, 128.4, 103.4, 63.1, 53.5, 
49.8, 17.7; HRMS (EI+) m/z calcd for C15H17N2O4S ([M+H]+) 321.0904, found 321.0898. 
 
 
 
 
 
3-(5-(Methoxycarbonyl)-6-methyl-4-phenyl-2-thioxo-3,4-dihydropyrimidin-1(2H)-
yl)propanoic acid (2.57). To a solution of 2.55 (20.2 mg, 0.0580 mmol, 1.0 equiv) in THF/water 
(3:1, 1.07 mL THF, 356 uL THF, 0.04 M) was added 1 M NaOH (69.0 uL, 0.0690 mmol, 1.2 
 97 
equiv). The reaction mixture was stirred at room temperature for 2 h, quenched using 1 M HCl (1 
mL), and extracted using EtOAc (5 mL, 3x). The combined organic extracts were dried 
(Na2SO4), concentrated under reduced pressure, and dried using high vacuum to afford 2.57 
(17.0 mg, 0.0508 mmol, 88%) as a white foam: IR (neat) 3396, 3075, 2919, 1705, 1655, 1530, 
1448, 1228, 1185, 1103, 1027, 807, 706 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.81 (bs, 1 H), 
7.36-7.28 (m, 5 H), 5.63 (s, 1 H), 4.33-4.25 (m, 1 H), 3.75-3.65 (m, 1 H), 3.69 (s, 3 H), 3.09-2.99 
(m, 1 H), 2.67-2.59 (m, 1 H), 2.31 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 175.7, 175.4, 165.6, 
142.5, 140.8, 129.0, 128.5, 126.8, 102.9, 62.3, 51.5, 48.3, 31.5, 18.3; HRMS (EI+) m/z calcd for 
C16H19N2O4S ([M+H]+) 335.1060, found 335.1051. 
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4.0  APPENDIX A 
Selected NMR Specta: 
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